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Older adults comprise a significant proportion of the population of New 
Zealand (NZ) and are known to be prescribed the highest number of 
medications. Several medications have to be prescribed with caution in older 
adults due to their compromised biological functions that can impact and 
reduce drug clearance. Potentially inappropriate medications (PIMs) may be 
defined as the prescription of drugs where the risks outweigh the clinical 
benefits or there may be under-prescribing of beneficial treatments. Over the 
last 3 decades, the global prevalence of prescribing PIMs has been reported 
from 5.2% to over 85%. PIMS may be identified by the application of 
criterion based explicit screening tools, of which the Beers criteria are 
commonly used to assess potentially inappropriate prescribing of 
medications in older adults.  
The overarching aim of the thesis was to assess medication appropriateness 
in older adults and suggest therapeutic alternatives for the currently 
prescribed medications with anticholinergic properties in individuals with 
dementia. 
 In the first phase of our project, a literature review of the existing tools for 
reducing PIMS was undertaken to assess the merits and demerits of each tool 
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with a view to suggest methods to reduce inappropriate prescribing which 
include medication review for each individual, deprescribing, and 
developing guidelines for appropriate prescribing. Through the literature 
review of existing explicit and implicit tools for identifying PIMS 
prescription, we could substantiate that the Beers criteria is a comprehensive 
screening tool that has been validated by a systematic literature review, 
evaluated by a Delphi consensus, and has shown good predictor validity in 
different settings. Hence, the Beers criteria was utilized for all the analytical 
studies conducted thereafter.   
We observed a high prevalence of prescription of potentially inappropriate 
medications in community dwelling older adults in NZ utilizing the Beers 
criteria and the PHARMS- interRAI-HC dataset. The International Resident 
Assessment Instrument-Home Care (interRAI-HC) is a standardized and 
internationally validated comprehensive geriatric risk assessment for older 
adults living in the community with complex care needs. In NZ a 
standardized interRAI-HC has been implemented for conducting all 
community care assessments in older adults needing publicly funded long-
term community services or aged residential care. The ubiquitous nature of 
the interRAI-HC assessment accounts for numerous social, psychological, 
and clinical risk factors when examining health outcomes in older adults. 
The interRAI-HC database is linked to several NZ Ministry of Health 
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national collections, including prescription use [the Pharmaceutical Claims 
Data Mart (PHARMS database)], hospital discharges (National Minimum 
Dataset), mortality data, and laboratory collections. The Pharmaceutical 
Claims Data Mart (PHARMS) is utilized by the Pharmaceutical 
Management Agency (PHARMAC) and the Ministry of Health, NZ to 
remunerate pharmacists for dispensing medications that are publicly funded, 
as well as to help PHARMAC in its management of the national budget of 
medications. The Ministry of Health provides PHARMS extracts with 
individual‐level prescription data along with the unique encrypted National 
Health Index (NHI) number for each individual. 
We then analysed the factors associated with prescribing PIMS, and found 
that there was a higher probability of prescribing PIMs in males, individuals 
aged 65-75 years, NZ Europeans, those who were prescribed a greater 
number of medications, and those who reported poor self-health, compared 
to their counter-parts. Individuals diagnosed with certain disorders like 
dementia, insomnia, depression, cancer, anxiety; or those who were 





Dementia is one of the principal syndromes linked with disability and 
dependence among older adults, and is a major challenge to individuals, 
communities, and societies worldwide. The global incidence of dementia is 
expected to rise to 81 million by 2040, primarily due to the progressive 
nature of the disorder, which involves worsening neurocognitive impairment 
and loss of basic functions in daily life. In 2016, the estimated prevalence of 
dementia in NZ was more than 62,000, which is predicted to increase to 
170,000 in 2050. In one of our studies utilizing the PHARMS and interRAI-
HC linked dataset, we observed that the prevalence of dementia was 13%, 
which was diagnosed by the Minimum Dataset Cognitive Performance 
Scale. 67% of the individuals with dementia were prescribed PIMs, and the 
medications with anticholinergic properties (MAP) constituted 60%.  
MAP bind to the muscarinic receptors and block acetylcholine 
neurotransmission, which regulates many central nervous system (CNS) and 
peripheral nervous system (PNS) actions MAP are prescribed excessively 
for Parkinson’s disease, depression, overactive bladder, allergies, 
inflammatory bowel disorders, and epilepsy. MAP are specifically 
associated with negative outcomes in older adults diagnosed with dementia, 
such as worsening of cognitive function, sustained cognitive defects, and 
increased mortality. They are notorious for their central side effects such as 
impaired concentration, confusion, attention deficit, and impairment of 
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memory, and peripheral side effects, which include dry mouth, constipation, 
urinary retention, and bowel obstruction. MAP may also inhibit the potential 
benefits of cholinesterase inhibitors such as Donepezil, Rivastigmine, and 
Galantamine, which is the main pharmacological class, currently approved 
for the management of dementia. 
Based on the current literature review of the anticholinergic burden (ACB) 
scales and serum anticholinergic activity of various medications, we collated 
known information of the level of anticholinergic activity for medications 
listed in the NZ formulary, and developed recommendations for prescribers, 
focussing on pharmacological alternatives for the currently prescribed MAP 
for older adults with dementia presenting with co-morbidities. Medications 
were classified according to the ATC-DDD methodology.  We sorted all the 
medications based on the high/moderate anticholinergic activity, and their 
low/no anticholinergic activity substitutes. To achieve an adequately 
comprehensive range of medications, all the existing scales measuring the 
anticholinergic activity of various medications were utilized. The current 
intervention was an attempt to identify medications with high or moderate 
anticholinergic activity (HOMAA) and substitute a low or no anticholinergic 
activity (LONAA) alternative for them wherever possible, according to the 
therapeutic classification of medications.  The ACB is the cumulative effect 
of prescription of MAP to each individual. The tool was applied to the New 
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Zealand’s PHARMS and interRAI-HC linked dataset to test the amendment 
in the ACB. Of the 75,410 community dwelling older adults aged 65 and 
above, 17 % were diagnosed with dementia. Almost half of these individuals 
were prescribed at least one MAP. Using a Paired-Samples Test, we 
compared the results of the ACB before and after the theoretical intervention 
of the pharmacological alternatives to MAP. By incorporation of the 
recommendations, we observed a significant reduction of the ACB by 0.49 
(95% CI, 0.47-0.51).  
The implementation of the recommendations for prescribing therapeutic 
alternatives to anticholinergic medications in this vulnerable population 
along with an awareness created among prescribers has the potential to 
reduce untoward effects associated with the prescription of these 
medications, slower cognitive decline, and decrease the risk of mortality; 
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        STRUCTURE AND OVERVIEW OF THESIS 
 
The thesis is presented in five parts, comprising five major studies.  
Part I comprises Chapter 1, which is an introduction to the thesis. It gives a 
synopsis of prescribing in older adults, the prescribing trend of potentially 
inappropriate medications in New Zealand, and describes the datasets 
utilized. 
In Part II, we have discussed the pharmacoepidemiology of prescribing 
potentially inappropriate medications in older adults in New Zealand. 
Chapter 2 is a literature review of the prevailing criteria for appropriate 
prescribing in older adults, which lists the usefulness and drawbacks of each 
criteria. Chapter 3 evaluates the prevalence of prescribing potentially 
inappropriate medications in community dwelling older adults of New 
Zealand utilizing the interRAI-HC dataset. Chapter 4 is a sequel to Chapter 
3, in which we have described the factors associated with inappropriate 
prescribing among older adults with complex care needs.  
Part III includes a detailed discussion on appropriate prescribing in 
individuals with dementia, and an emphasis on developing alternatives to the 
potentially inappropriate medications. Chapter 5 outlines the major 
determinants of prescribing potentially inappropriate medications in a 
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national cohort of community dwellers with dementia receiving a 
comprehensive geriatric assessment, of which a few of the modifiable factors 
include the prescription of medications with anticholinergic properties, a 
higher number of medications prescribed, poor self‐health. In Chapter 6, we 
have listed therapeutic alternatives to potentially inappropriate medications 
with anticholinergic properties in older adults with dementia, with an aim to 
reduce the anticholinergic burden. We then incorporated the tool in the 
interRAI-HC dataset, and checked for the reduction in the anticholinergic 
burden.  
Part IV comprises Chapter 7, which is mainly the discussion and conclusion 
of the thesis, and information for future research in this direction.  
Part V of the thesis includes the appendices and a list of references referred 
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The introduction provides an overview of prescribing medications in older 
adults in New Zealand, the prescribing trend of potentially inappropriate 
medications and how prescribing is assessed. A synopsis of the interRAI-HC 
and PHARMS dataset has been provided.  A brief description of dementia 
along with prescribing has been outlined with a focus on the prescription of 
medications with anticholinergic properties.  
  
1.1 Prescribing trends in older adults in New Zealand 
New Zealand (NZ) has witnessed a steady growth in the population of older 
adults in the last decade as the proportion of individuals aged 65 years and 
over increased from 12% in 2006 to 14% in 2013, and is estimated to 
comprise 21% of the population (1.1 million) by 2031.(1) A significantly 
greater number of medications are prescribed to this age group owing to the 
presence of multiple comorbidities, which is a major risk factor for 
increased adverse events, medication interactions, high health-care costs, 
hospital admissions, visits to the emergency department, prescribing 
cascades, morbidity, and mortality.(2, 3) It is arduous for medical 
practitioners to prescribe optimally in older adults, since the approved 
doses of medications are generally extrapolated from clinical trials, and 
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may not be suitable for the entire geriatric population.(4) Cautious 
prescribing of medications in older adults is necessary due to their 
compromised biological functions and age-associated variations in 
pharmacodynamics and pharmacokinetics, which influence and diminish 
medication clearance.(5)  
1.1.1 Potentially inappropriate medications (PIMs) 
Potentially inappropriate medications (PIMs) are those medications which 
should not be prescribed to most of the population, as the risks outweigh the 
clinical benefits or there may be under-prescribing of beneficial treatments, 
especially when there are safer and more effective alternative treatments 
available.(6)  
Over the last three decades, it has been recognised that prescribing PIMs to 
older adults is considered unsafe, since it is a pervasive public health 
concern, with reported statistics of 5.2 per cent to more than 85 per cent of 
older adults being exposed to PIMs globally.(7-11) Earlier work conducted 
by one of my supervisors, Nishtala P et al, in NZ has reported high incidences 
of prescription of PIMs in older adults.(12-14)  Prescription of medications 
to older adults is problematic in the presence of cognitive decline, multiple 
morbidities and frailties.(15) Particular emphasis has been given on 
understanding the predictors of prescribing PIMS in individuals with 
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dementia; and there is a growing body of evidence for factors influencing the 
prescription of PIMS in older adults with complex care needs. The literature 
shows a few studies conducted globally in community dwelling older adults 
(16, 17)  which detail the factors associated with the prescription of PIMS in 
older adults. Studies conducted across Europe (18) and in Canada (19) have 
shown associations of various sociodemographic and clinical factors linked 
with prescription of PIMS in individuals with dementia. My thesis outlines 
the factors associated with prescription of PIMS in older adults living in the 
community with complex care needs in NZ, highlighting the prescription in 
individuals with dementia.   
1.1.2 Quantification of PIMs 
PIMs may be identified by the application of criterion-based explicit 
screening tools, of which the Beers Criteria are commonly used to assess 
inappropriate prescribing of medications in older adults.(12, 20) The 
American Geriatric Society Beers criteria were the first set of explicit criteria 
for identifying the prescription of PIMs in older adults, published in 1991 
and subsequently updated in 1997, 2003, 2012, and 2015. The Beers criteria 
are derived from expert opinions, published reviews, and consensus 
techniques, and seldom require a clinical judgment for its application.(21) 
The Beers criteria is primarily based on medications available in the USA. It 
lists medications that are potentially inappropriate and hence, could be 
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avoided in general in older adults, prescribed at reduced dosage, or used with 
caution in older adults with certain diseases or syndromes. The basis of 
development is to alert prescribers about medications that are frequently 
problematic, and therefore, should be avoided in the majority of older adults.  
Globally conducted epidemiological studies utilizing the Beers criteria have 
reported figures of 5.2% to over 85% of older adults exposed to at least one 
PIM.(7-11) These criteria guide health-care professionals to improve the 
safety of prescribing medications for older adults by reducing the risk 
associated with unnecessary polypharmacy, medication interactions, and 
adverse reactions.(22) A novelty in the 2015 Beers criteria are the lists of 
specific medications that should be avoided or have their dose adjusted based 
on the individual’s kidney function. The interactions of medications found 
to be associated with potential complications in older adults have also been 
introduced in the updated 2015 Beers criteria.(21)  
The STOPP criteria (Screening Tool of Older Persons’ potentially 
inappropriate Prescriptions) (23) was developed in Ireland as a screening tool 
for the assessment of inappropriate prescribing and potential prescribing 
omissions at the individual patient level. It lists appropriate as well as 
inappropriate medications prescribed in older adults.(24) 
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Implicit criteria such as the Medication Appropriate Index focus on the 
patient’s preferences, and the outcome is dependent on the prescriber’s 
knowledge.(2) Owing to the high rate of prescribing PIMs in older adults, it 
is necessary to evaluate the practical application of the existing criteria to 
reduce PIMs, and identify methods to decrease inappropriate prescribing.  
 
1.2. International Resident Assessment Instrument-Home Care  
The International Resident Assessment Instrument-Home Care (interRAI-
HC) is a standardized and internationally validated comprehensive geriatric 
risk assessment for older adults living in the community with complex care 
needs.(25) The introduction of Resource Utilisation Groups (RUGs) is an 
opportunity to better align aged care with other parts of the health sector 
strengthening the continuum of care for older people. interRAI is ideally 
placed to support this alignment. More than 25 assessments are available for 
many different settings and populations, including acute care and mental 
health. All interRAI assessments share a common language and concepts, 
making assessment data transferable across settings and locations. Many 
countries use a standardised assessment to determine an individual’s level of 
need for long-term care. In many of these classification systems, the levels 
of care determined by the assessment instrument are directly connected to 
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the level of funding available to care for the individual. RUGs directly match 
funding to a resident’s needs and care plan. The RUGs system has proven to 
be extremely robust and it is used in several nations as a basis of a payment 
system for funding long-term care, including the United States, Australia, 
New Zealand, Canada, Iceland and Finland.(26) NZ is the only country 
wherein a standardized interRAI-HC has been implemented for conducting 
all community care assessments in older adults needing publicly funded 
long-term community services or aged residential care.(27) Individuals are 
referred to trained interRAI-HC assessors by a health practitioner. Assessors 
visit clients at the clients’ address to develop individualized care plans 
according to a standardized protocol. Participants are explicitly questioned 
if they consent to their de-identified interRAI-HC information being used for 
planning and research purposes. After obtaining consent, all data is stored in 
the electronic interRAI-HC database, maintained by NZ’s Technical 
Advisory Services (TAS). With approval, de-identified data is released by 
TAS, through the Ministry of Health for research purposes.(28) Individual-
level data from the interRAI-HC suite include demographics, medical 
ailments, frailty, cognitive function, physical function, and related 
information. The ubiquitous nature of the interRAI-HC assessment accounts 
for numerous social, psychological, and clinical risk factors when examining 
health outcomes in older adults. The interRAI-HC database is linked to 
                                                        
                                                                                                      Chapter 1: Introduction to the thesis 
8 
 
several NZ Ministry of Health national collections, including prescription 
use [the Pharmaceutical Claims Data Mart (PHARMS database)], hospital 
discharges (National Minimum Dataset), mortality data, and laboratory 
collections.(29) The NZ version of the interRAI-HC contains 236 individual 
questions, assessed over 20 domains, which generate 27 validated instrument 
scores that guide patient management.(27) 
The interRAI-HC assessment is an international collaborative to improve the 
quality of life of vulnerable persons through a seamless comprehensive 
geriatric assessment system. The interRAI-HC instruments have been 
adopted around the world, bringing a standard level of care to older adults. 
It is a collaborative network of researchers in over 30 countries, committed 
to improving care for persons who are disabled.(30, 31) The interRAI-HC 
assessments provide a unique opportunity to re-evaluate prescribing in high-
risk populations to reduce PIMs and polypharmacy. An older person receives 
a proactive assessment if they have any risk factors; are referred following 
screening; are referred by community workers, family/whänau or carer; or 
are in contact with health or social services. That includes most of the older 
adults aged 65 and above, and Maori/Pacific/ those with pre-existing 
disabilities aged 55 and older.(32) 
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1.3 Pharmaceutical Claims Data Mart (PHARMS) 
The Pharmaceutical Claims Data Mart (PHARMS) is utilized by the 
Pharmaceutical Management Agency (PHARMAC) and the Ministry of 
Health, NZ to remunerate pharmacists for dispensing medications that are 
publicly funded, as well as to help PHARMAC in its management of the 
national budget of medications.(33, 34) PHARMS provides information on 
all prescription claims made by community pharmacists funded by the 
PHARMAC. The Ministry of Health provides PHARMS extracts with 
individual‐level prescription data along with the unique encrypted National 
Health Index (NHI) number for each individual, without disclosing the 
identity of the individuals. The NHI number is assigned to every person who 
uses health and disability support services in NZ, and enables individual 
records to be linked between various national health data collections. Each 
prescription record includes the sex, date of birth, prioritized ethnicity, and 
District Health Board of domicile of the patient; medication name; date of 
medication supplied; daily dose; frequency; and total quantity supplied for 
each NHI number.(35)  
 
1.4 Dementia 
Dementia is a chronic and progressive syndrome, linked with disability and 
dependence among older adults, and is a major challenge to individuals, 
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communities, and societies worldwide. It is characterised by the worsening 
of cognitive function and the inability to perform routine activities 
effectively.(36, 37) The global incidence of dementia is expected to be 
around 10 million each year, primarily due to the progressive nature of the 
disorder, which encompasses worsening neurocognitive impairment and loss 
of basic functions in daily life.(38-40)  
1.4.1 Diagnosis of Dementia in New Zealand 
Symptoms of cognitive decline are assessed when first reported or noticed. 
In many cases, reassurance that the symptoms are due to age-related 
cognitive decline are appropriate. However, if the symptoms are indicative 
of a potentially clinically significant change in cognitive function or are 
affecting the person’s activities of daily living, they are assessed for 
dementia. Brain imaging with computed tomography (CT) is recommended 
when assessing people for dementia to exclude structural cerebral 
pathologies or potentially reversible conditions, and to assist with subtyping, 
management planning and as a clinical baseline if a dementia diagnosis is 
made. If subtyping will not change the management plan or the prognosis, 
e.g. a person of advanced age with established severe dementia, then a head 
CT may not be necessary. The General Practitioner Assessment of Cognition 
(GPCOG) takes less than five minutes to administer and is validated for use 
in primary care. If the results suggest impairment or it is already apparent 
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that some impairment is present, a more comprehensive evaluation is 
undertaken. The recommended test for use as part of this assessment is the 
Mini-Addenbrooke’s Cognitive Examination (Mini-ACE or M-ACE). This 
test also takes about five minutes to administer and is validated for use. Mini-
ACE will be the recommended test on the cognitive impairment pathway on 
local community health pathways platforms once they are updated on 1 
September, 2020. Mini-Addenbrooke’s Cognitive Examination (Mini-ACE 
or M-ACE) will now be the recommended test for assessing cognitive 
function in New Zealand. Until recently, the Montreal Cognitive Assessment 
(MoCA) was the most frequently used cognitive screening tool in primary 
care in New Zealand and the preferred cognitive assessment tool listed by 
Health Pathways.(41) 
The Cognitive Performance Scale (CPS) is a valid and reliable seven‐point 
hierarchical scale derived from the Minimum Dataset (MDS) that rates 
impairment from intact memory to very severe memory loss.(42) The CPS 
collates data on comatose status, short‐term memory, cognitive skills for 
daily decision- making, being understood by others, and self‐performance in 
eating; with scores ranging from 0 (intact memory) to 6 (very severe memory 
impairment). The CPS has been shown to be highly correlated with the Mini‐
Mental State Examination in a number of validation studies. All interRAI 
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assessments across NZ utilize the MDS-CPS score for assessment of the 
cognitive function.  
Dementia was diagnosed in one in every four interRAI‐HC evaluated 
individuals in 2016-2017 in NZ, of which 35% needed extensive assistance 
or were completely dependent, and 30% showed daily episodes of disturbing 
behaviour, such as being abusive or wandering.(30) It is difficult to prescribe 
medications for older adults with dementia primarily because of the risks 
associated with the prescription of multiple medications and their associated 
costs, cognitive decline, behavioural and psychological disturbances.(43, 44) 
A recent literature review reported the prevalence of PIMs prescribed as 
16.2% to 33% among five studies conducted in ambulatory home‐dwelling 
patients diagnosed with dementia, and PIMs were associated with gender, 
ethnicity, number of medications prescribed, and varied medical 
conditions.(10) Research has primarily focussed on the detection of 
potentially modifiable risk factors such as medication induced cognitive 
impairment due to lack of a completely effective clinical management for 
age related neurodegenerative disorders.(45) Knowledge of the prevalence 
and determinants of prescribing PIMs can prevent adverse effects and 
improve the quality of prescribing in older adults. While conducting a 
literature review, no study was found which evaluated the predictors of 
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prescribing PIMs in older adults with dementia in NZ, receiving a 
comprehensive geriatric risk assessment.  
1.5 Medications with anticholinergic properties  
Anticholinergic drugs bind to the muscarinic receptors and block 
acetylcholine neurotransmission, which regulates many central nervous 
system (CNS) and peripheral nervous system (PNS) actions. Medications 
with anticholinergic properties (MAP) are prescribed excessively for 
depression, Parkinson’s disease, peptic ulcer, inflammatory bowel 
syndrome, overactive bladder, allergies, epilepsy, etc.(46-48) Most of the 
first generation antihistamines, tricyclic antidepressants, antipsychotics have 
unintended anticholinergic side effects, which are not their principal 
therapeutic activity.(47) Individuals diagnosed with dementia exhibit a 
greater risk of developing medication induced cognitive impairment as MAP 
accelerate neurodegeneration by impeding the immune regulatory process of 
cholinergic nicotinic receptors which inhibit inflammatory reactions in the 
nervous system.(49, 50) Prolonged exposure to MAP has been linked to 
long-term cognitive decline in many studies conducted globally.(45, 47, 49, 
51, 52) Research suggests prescriptions of alternatives to these MAP to delay 
cognitive decline.(53-55) The Anticholinergic burden (ACB) is the 
cumulative effect of prescription of MAP to each individual.(56, 57) Many 
clinical scales have been designed globally to detect and assess the 
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prescription of MAP; however, there is no ideal measure, as the number of 
medications listed and the rating of the anticholinergic activity for each 
medication vary considerably.(56, 58) Also, a number of scales classify 
medications with high and moderate anticholinergic activities, but none of 
these give a comprehensive list of the therapeutic alternatives to MAP 
prescribed for comorbidities in older adults with dementia.   
 
1.6 Aim of the thesis   
The overarching aim of the thesis is to assess medication appropriateness in 
older adults and suggest therapeutic alternatives for the currently prescribed 
medications with anticholinergic properties in individuals with dementia. 
1.6.1 Specific objectives 
i. To evaluate the practical application of the existing criteria for appropriate 
prescribing, and identify methods to decrease inappropriate prescribing   
ii. To examine the prevalence of exposure to PIMs, the most common PIMs 
prescribed, the prevalence of prescription of PIMs that may potentially 
exacerbate existing disease or syndrome in older New Zealanders, and 
medications to be used with caution, applying the 2012 and updated 2015 
Beers criteria. 
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iii. To examine the prevalence of potential clinically important non-anti-
infective medication interactions that should be avoided in older adults, 
utilizing the updated 2015 Beers criteria. 
iii. To identify factors associated with prescribing potentially inappropriate 
medications (PIMs) in older adults (≥65 years) with complex care needs, 
who have undertaken a comprehensive geriatric risk assessment. 
iv. To identify the factors associated with inappropriate prescribing in older 
adults diagnosed with dementia, utilizing the 2015 version of the Beers 
criteria, and the 2015 interRAI-HC dataset. 
v. To develop a comprehensive list of therapeutic alternatives to medications 
with anticholinergic properties prescribed for comorbidities in individuals 
with dementia. 
 
1.7 Research hypothesis 
Hypothesis 1: There is a high prevalence of prescription of PIMs in 
community dwelling older adults in NZ with complex-care needs. 
Hypothesis 2: Many socio-demographic and clinical factors contribute to the 
prescription of PIMs in older adults 
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Hypothesis 3: The majority of the community dwelling individuals 
diagnosed with dementia are prescribed potentially inappropriate 
medications, especially those with anticholinergic properties.  
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All three authors contributed equally to the manuscript. PN designed the 
study, SB and TC did the literature review and wrote the paper. The paper 
was reviewed by all the authors.  
2.1 Context 
Several medications need to be prescribed prudently in older adults, because 
of age-associated variations in pharmacokinetics and pharmacodynamics.(5) 
There is substantial evidence implicating inappropriate prescribing as a 
potential predictor of negative health outcomes, including adverse events, 
medication interactions, increasing health-care costs and hospital 
admissions, and a proportionate rise in morbidity and mortality in older 
adults.(2, 3)  
2.1.1 Epidemiology of PIMs 
Prescription of potentially inappropriate medications (PIMs) in older adults 
is a pervasive public health concern and has received significant 
consideration globally for several decades with reported figures of 5.2 per 
cent to more than 85 per cent.(7, 11) Many studies (59-61) have knowingly 
linked the prescription of inappropriate medications with higher health care 
costs. In a systematic review conducted in Finland, it was found that 
prescription of PIMs had a statistically significant effect on health care 
utilization, including increased rates of hospitalization, inpatient, outpatient, 
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and emergency department visits among older adults.(62) The prescription 
of PIMs in older adults has been on the rise worldwide, which could be 
attributed to the widespread increase in the prescription of medications for 
the management of multiple chronic medical illnesses.(63) Prescribing 
medications to older adults is problematic in the presence of cognitive 
decline, multiple morbidities, and frailty. While formulating therapeutic 
aims for older adults, clinicians have to consider the indications for 
prescribing, the time-to-benefit, concomitant medications, side effects, 
compliance, co-morbid conditions, patient preferences, and the patient’s 
remaining life expectancy.(2, 64) As excessive medications are becoming 
available, and longevity continues to increase, there will be a further increase 
in the consumption of prescription medications among older adults, and the 
incidence of potentially inappropriate prescribing will continue to grow 
proportionately.(65)  
Aim: In view of the high rate of prescription of PIMs in the older adults, we 
have attempted to illustrate the popular explicit and implicit criteria available 
globally for assessing appropriate prescribing.in order to suggest methods to 
reduce inappropriate prescribing. (66) 
 
                                                        




The Ovid MEDLINE®, Embase, PubMed, Scopus, and International 
Pharmaceutical Abstracts databases were searched using the keywords 
‘prescribing criteria’, ‘prescribing, indicators’, ‘deprescribing’, ‘appropriate 
prescribing’, and ‘older adults’ (including synonyms), by the MeSH or major 
descriptor headings. The search was restricted to studies undertaken in 
humans, which were published in English during the last 30 years (1987–
2017), and in individuals over 65 years of age. In addition, a citation analysis 
with the aid of Web of Science was conducted to track prospective citing of 
references of the selected articles. Reference lists of retrieved articles were 
studied for the purpose of finding additional articles not identified in the 
original database searches. Studies that were pertinent to the description of 
appropriate prescribing in older adults were chosen. The most recent studies 
conducted globally were prioritized. 347 articles were downloaded from 
computerised databases, 45 were manually searched, 63 duplicate records 
were removed, 196 articles were screened in total, and 108 of the full text 
articles were assessed for eligibility.  After excluding the articles based on 
the inclusion-exclusion criteria, 68 were included in the literature review. 
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Inclusion criteria Exclusion criteria 
Studies conducted in humans Animal or cell studies 
Studies in the English language Studies in other languages 
Studies involving older adults:>65 
years of age 
Studies in which individuals are less 
than 65 years of age 
Recent studies (<30 years in 2017) Studies conducted before 1987 
 
 Summary of the Criteria Measuring PIMs 
Several criteria have been implemented across many countries with a view 
to reduce the prevalence of the prescription of PIMs in older adults (Tables 
2.1–2.4). 
2.2.1 Explicit Criteria 
These criteria are established by expert consensus, and are used to generate 
lists of medications to be avoided in older adults. It is often easier to 
implement explicit criteria in routine clinical practice, because no extensive 
clinical judgement is required for their implementation, and there is a limited 
number of medications and clinical conditions specified. Explicit criteria are 
often utilized in studies of health outcomes and to gauge the prevalence of 
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PIMs prescribing. Quite a few of these criteria are purely explicit or have 
both implicit and explicit measures embedded in them, and are usually 
medication or disease oriented, rather than being patient oriented.(67) Most 
available explicit criteria are based on the sequential Beers criteria, as each 
updated version of the Beers criteria includes most of the contemporary 
medications and health conditions.(68) The explicit criteria include a list of 
medications to be avoided, which are perceived to have increased 
possibilities of negative health outcomes in older adults. Expert opinions, 
literature reviews, and consensus statements are taken into consideration 
while developing explicit criteria because there is insufficient evidence from 
randomised controlled trials (RCT) to guide prescribing in the entire 
population of older adults globally. However, it is significant to note that 
explicit criteria may not encompass all aspects that outline the quality of 
prescribing for older adults, and they must be updated and validated 
frequently.(2, 68) Of the studies conducted internationally to validate the 
reliability of the explicit criteria, three of them do not include under-
prescribing of medications.(69-71) 
2.2.2 Implicit Criteria 
Implicit criteria for reducing inappropriate prescribing generally focus on the 
patient, rather than on medications or diseases per se. Implicit criteria 
account for the patients’ preferences; nonetheless, they are time consuming, 
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and the outcomes depend on the prescriber’s knowledge and attitudes and 
may have low reliability.(2) Implicit criteria may be used as a supplement, 
but not as a substitute for clinical judgment, when optimising medication use 
in older adults.(72) The ideal criteria should consider the management of co-
morbid disorders, under-prescribing of guideline recommended medications, 
medication interactions, polypharmacy, patient preferences, life expectancy, 
and clinical information pertaining to older adults.(73) 
 
2.3 Results 
The Beers and STOPP/START criteria were classified as globally most 
commonly used explicit criteria. The Australian Prescribing Appropriate 
Criteria, the Improved Prescribing in the Elderly Tool, the French Consensus 
Panel, the Forta-Fit for Aged classification, and the Priscus list were 
categorized as country specific explicit criteria. A few criteria not commonly 
utilized were listed as a separate table. Among the implicit criteria, the 
Medication Appropriateness Index, the Systematic Tool to Reduce 
Inappropriate Prescribing, the Revised Swedish Indicators were described. 
A total of sixty-eight studies were included for the literature review. In the 
tables we have described each criteria by presenting a summary from the 
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studies included in the review; we have also delineated the usefulness, 
validity and drawbacks of each criteria.   
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Table 2.1: Globally most commonly used explicit criteria 




Beers Criteria 2015, 
USA 
1. Seminal criteria 
for assessing 
PIMs.(64) 
2. Based on 
medications available 
in the United 
States.(74) 
3. To alert 
prescribers on 
medications that are 
frequently 
problematic, and thus 
should be avoided in 
majority of older 
adults.(74) 






settings of care, 
except hospice and 
palliative care.(21) 
List medications 
which are potentially 
inappropriate and 
hence could be 
avoided in general in 
older adults, and 
prescribed at reduced 
dosage or with 
caution in older 
adults with certain 
diseases or 
syndromes.(21) 
1. For monitoring the 








prescription in older 
adults.(75) 
1. Do not identify all 
cases of potentially 
inappropriate 
prescribing. 
2. Do not predict 
functional decline in 
community dwelling 
older adults. 







medications not to be 
prescribed. 
4. Not applicable to 
patients in the 
palliative and hospice 
care.(75, 76) 
A study conducted in 
hospital-discharged 




prescribing as 63%, 





A study conducted in 
Long-term-care 
facilities in Canada 
found a prevalence of 
PIMs as 81-86%. 
(78) 
1. Systematic 
literature review and 
evaluation by the 
Delphi 
consensus.(21) 
2. The predictive 
validity of Beers 
criteria in different 
settings suggests 
generalizability of 
the evidence with 
respect to the adverse 
events and costs.(79) 
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1. Developed as a 
screening tool to 
identify problems at 
the individual patient 
level.(80) 
2. Adopted globally 
for assessment of 
inappropriate 
prescribing.(81) 
3.  Structured 





groups of  
medications.(81) 
Primary care setting, 
acute hospital care, 
and in nursing home 
care.(81) 





2. Lists appropriate 




3. It has implicit and 
explicit criteria.(81) 




2. Increasingly used 
to assess the 
prescribing quality at 
both the level of the 
practitioner and the 
practice.(80) 
3. Can be utilized to 
support medication 
reviews, as it is a 
comprehensive 
screening tool that 
enables the 
prescribers to 
appraise the health of 
the older adults, in 
context of their 
comorbidities.(82)  
4. Computerized 
application of the 
criteria can support 
the routine 
assessment of 
prescribing for older 
adults, by reducing 
the time to analyse 
inappropriate 
1. Adequately large 
prospective trials are 
needed to determine 
if rigorous 
application of the 
STOPP and START 
tools have tangible 
benefits in terms of a 
decrease in adverse 
medication reactions, 
cost, hospitalization 
and mortality.(83)  
2. The practical 
applicability with 
respect to clinical and 
financial benefits in 
daily general practice 
and community 
pharmacy is not yet 
established.(83) 
3. There are very few 
doses of medications 
mentioned which are 
inappropriate. 




older adults seldom 
associate with 
1. 41.5% of the 
inpatients of a 
hospital in Spain 
were prescribed 





2. STOP-Frail is an 
explicit list of 27 
PIMs, which can be 
applied to frail older 
adults with limited 
life expectancy in 
any healthcare 
setting.(86) 
A systematic review 
of the 
STOPP/START 
criteria conducted in 
Novo Scotia, Canada 
observed reduced 
PIM rates in all 
studies, and a 
reduction in the falls, 
delirium episodes, 
length of stay in 
hospitals, care visits, 
and medication costs, 
1. Delphi consensus 
conducted.(88) 












Chapter 2:  An overview of the existing criteria for appropriate prescribing                                                     




prescriptions with the 
114 criteria. (80) 
5. The potential to 
incorporate the 
criteria in electronic 
medical record 
databases, which are 
now widely used for 
evaluation and 
feedback purposes in 
primary care, needs 
further exploration. 
STOPP/START 
criteria. (83, 84) 
5. The criteria should 
be preferably 
combined with 
implicit criteria. (84) 
but no improvement 
in quality of life and 
mortality. (87) 
Chapter 2:  An overview of the existing criteria for appropriate prescribing                                                     







Table 2.2: Popular country-specific criteria for assessing PIMs 
Criteria 
 
Description  Usefulness Validity  Drawbacks including 
generalisability 
Australian prescribing 
appropriateness criteria, 2008 
(73) (90) (70, 91) 
1. Applicable to community, 
hospital, residential home, care 
home or nursing home older 
adults.  
2. Structured according to the 
physiological systems, and 
addressed to pharmacological 
groups of  medications.  
3. Lists appropriate as well as 
inappropriate medications 
prescribed.  
4. It has implicit and explicit 
criteria. 
 
1. Addresses optimal and 
suboptimal prescribing of 
medications.  
2. Provides evidence-based 
treatment in the oldest old. 
3. Encourages shared decision-
making. 
4. Encompasses medication 
duplication and under-
prescribing.  
5. The guidelines used to derive 
the criteria may be applied to 
develop various country-
specific criteria. 
1. The APAC criteria cross-
referenced the 50 highest-
volume medications prescribed 
to older Australians in 2006 
with the most common reasons 
for patients to consult general 
practitioners.  
2. The tool is derived from an 
analysis of the most common 
medications dispensed in 
Australia, and the most 
common conditions for which 
older adults residing in 
Australia receive medical care. 
3. Delphi consensus conducted. 
Due to the differences in the 
prescribing patterns in various 
countries, these criteria may 
have limited generalisability 
worldwide. 
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Improved Prescribing in the 
Elderly Tool, Canada, 2000 
(92, 93) (88) 
1. Updated version of the Mc 
Leod criteria.  
2. Comprises of ten 
medications–disease 
interactions, two inappropriate 
medication classes, and two 
recommendations for the 
duration of therapy. 
3. Criteria based on 
pharmacological groups of  
medications. 
1. A tool for quick analysis of 
potentially inappropriate 
medications. 
2. Lists inappropriate 
medications prescribed.  
 
No information on validity. Mainly comprise of 
psychotropic and cardiovascular 
medications, and overlook 
many other well-recognized 
inappropriate prescriptions; 
hence, may not be generalized 
to prescribing in older adults. 
The French Consensus panel 
list, 2007 (94) (71) 
1. Developed from the Beers 
criteria, the Canadian criteria, 
the criteria adapted to French 
practice, and the guidelines of 
the French Medicine Agency on 
medication prescribing in older 
adults.  
2. 34 inappropriate practices in 
prescribing with 
recommendations of alternative 
therapies (29 medications or 
medication classes that should 
be avoided, 5  medication–
disease interactions). 
3. Criteria based on 
pharmacological groups of 
1. Provides a concise 
explanation of 
inappropriateness 
2. Includes medication 
duplication. 
3. Safer alternatives are 
suggested. 
Delphi consensus conducted.  
 
The guidelines are adapted 
referring to the French drug 
formulary, and there are very 
few studies conducted to assess 
the criteria. Hence, it is not 
feasible to generalise the 
criteria. 
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medications and structured 
according to five syndromes. 
4. Lists inappropriate 
medications prescribed. 
FORTA- ‘Fit for the aged’ 
classification, Germany, 2015 
(95) (96) (97) 
1. 273 items consisting of the 
most frequently used substances 
for the long-term medication 
therapy of older adults.  
2. 29 diagnoses/indication areas 
were assigned positive and 
negative labels ranging from A 
- B - C - D according to the 
state of evidence according to 
risk/benefits and age-
appropriateness. 
3.  Criteria structured according 
to the physiological systems. 
4. Lists appropriate as well as 
inappropriate medications 
prescribed. 
1. Supports the screening for 
inappropriate medications and 
the omission of important 
medications, including sub-
optimal treatment in older 
adults. 
2. Has been shown to improve 
the quality of pharmacotherapy, 
and may ameliorate clinical 
endpoints including adverse 
reactions. 
1. Delphi consensus validations 
of country/region-specific 
FORTA lists were conducted in 
the UK/Ireland, France, Poland, 
Italy, Spain, the Nordic 
countries and the Netherlands.   
2.  Validated in a randomized, 
controlled, prospective trial.  
 
The application of FORTA is 
very challenging, and the 
beneficial results cannot be 
generalised, since no 
international studies have been 
conducted applying FORTA. 
The PRISCUS list, Germany, 
2008 (70, 98) (67) 
1. 131 criteria derived from the 
pre-existing criteria. 
2. Criteria based on 




on dose adjustment, and 
facilitates medication 
monitoring. 
Delphi consensus conducted. 
 
1. Most adverse medication 
events in older adults were not 
associated with the PRISCUS 
list medications, hence 
generalizability is challenging. 
Chapter 2:  An overview of the existing criteria for appropriate prescribing                                                     










3. 83 medications were termed 
PIMs according to the 
medication class. 
4. Lists inappropriate 
medications prescribed. 
2. There are no criteria for 
assessing the combination of 
medications. 
3. Does not include over the 
counter medications. 
The NORGEP Criteria, 
Norway, 2009 (99) (67, 70, 
100) 
1. 37 explicit criteria based on 
pre-existing criteria and clinical 
experience. 
2. Intended for use in general 
practice and for home-dwelling 
older adults.  
3. Criteria based on 
pharmacological groups of 
medications. 
 
1. Inclusive of the deprescribing 
component as well. 
2. Addresses medication 
combinations. 
3. Lists inappropriate 
medications prescribed. 
Delphi consensus conducted. 
 
1. Criticised for including 
several medications that are 
seldom utilized in clinical 
practice; therefore, not 
generalizable. 
2. Do not include medication -
disease interactions. 
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Table 2.3: Miscellaneous country specific criteria 
 
Austrian consensus panel list (101) 
The quality indicators for Assesing Care of Older Adults (ACOVE) (102)  
The EU(7) PIM list (103)  
The Health Plan Employer Data and Information Set (HEDIS) criteria(104) 
The List of Potentially Inappropriate Drugs for the elderly in Korea (105) 
The comprehensive protocol by Matanovic et al (92) 
The PIM-Taiwan criteria (106) 
The criteria for high-risk medication use in Thai older patients (93) 
The Zhan classification (107)  
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Table 2.4: Implicit criteria adopted globally for assessment of PIMs 
Criteria Description  Usefulness Disadvantages 
Medication 
appropriateness index 
(MAI), USA, 1994 
(108, 109) 
(110) (111) 
1. First implicit criteria used in research and clinical 
practice. 
2. Ten criteria worded as questions that allow three 
rating choices according to the appropriateness. 
3. Requires clinical information and acumen for its 
application. 
4. A study conducted recently in Australia demonstrated 
the reduction in MAI scores post intervention. 
 
1. Applicable to all older 
adults. 
2. Lists appropriate as well 
as inappropriate medications 
prescribed. 
3. Criteria based on 
pharmacological groups of 
medications. 
1. Does not prioritise which 
medications should be modified. 
2. Seldom addresses aspects of 
suboptimal prescribing (i.e. 
polypharmacy or underuse of 
essential medications). 
3. May be subjected to reliability 
issues when there is more than a 
single evaluator. 
The Systemic Tool to 
Reduce Inappropriate 
Prescribing , 2012 (112) 
(113) 
 
1. Includes a combination of implicit criteria and the 
START/STOPP explicit criteria. 
2. Actively involves the patient, and includes patients’ 
medication histories and preferences. 
3. Promotes co-operation among different health care 
providers (doctors, pharmacists, and home care nurses). 
4. Focuses on the evaluation and monitoring of changes 
in the medication regimen. 
5. The comprehensive pharmacotherapeutic analysis in 
STRIP includes under-prescribing, over-treatment, 
potential adverse effects, recommended dosage 
adjustments, medication effectiveness, clinical 
1. Applicable to all older 
adults. 
2. Lists appropriate as well 
as inappropriate medications 
prescribed. 
3. Has been included as part 
of a Dutch multidisciplinary 
guideline on polypharmacy 
in older adults. 
4. The STRIP assistant is a 
web application. 
1. Can be tedious, and respondents 
perceived using the STRIP Assistant 
as only marginally acceptable.  
2. Has not been validated in clinical 
practice, and hence lacks sufficient 
relevance. 
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interactions and medication adherence, including 
practical challenges with medication use. 
 
5. Criteria structured 
according to the 
physiological systems.  
6. It has both implicit and 
explicit criteria. 
.  
The revised Swedish 
indicators (2010) 
 (67, 100) 
 
1. Classified as 
 (a)  Medication -specific (encompassing choice, 
indication, and dosage of medications, aspects of 
polypharmacy, and  medication interactions) 
(b) Diagnosis-specific (incorporating rational, irrational 
and hazardous  medication use in 11 common disorders 
in older adults) 
 
1. They include criteria on 
medication omissions 
2. Applicable to all older 
adults. 
3. Lists inappropriate 
medications prescribed. 
4. Structured according to the 
physiological systems, and 
addressed to 
pharmacological groups of 
medications. 
5. It has both implicit and 
explicit criteria. 
 
Dearth of information regarding 
patient adherence to the 
pharmacological therapy, and further 
research is required to assess the 
proposed improved health status of 
older adults. 
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The health and functional status of older adults vary widely; so a “one size fits 
all” approach to prescribing is sub-optimal for meeting individual patient 
needs.(109, 114) Individual assessments that review the need for continuing each 
medication may help in simplifying treatment regimens, and in turn reduce the 
prescribing of PIMs. A Cochrane review in 2013 verified that medication reviews 
of inpatients, led by health care professionals, resulted in a 36 per cent reduction 
in emergency department visits.(115) If it is evident that the therapy prescribed 
is not appropriate as the illness progresses, a tailored approach for discontinuing 
medications may be favoured.(116) Interactive and continuous education of 
health professionals and patients, which includes discussion of evidence, local 
consensus, feedback on performance, and personal and group learning techniques 
facilitate appropriate prescribing.(117) 
2.4.1 Deprescribing  
Deprescribing is an initiative to reduce the utilization of redundant medications, 
especially PIMs, and it encourages the use of non-pharmacological alternatives, 
supervised by a health care professional, with the objective of managing 
polypharmacy and improving health outcomes.(118) Rational withdrawal of 
medications in older adults is prudent for obtaining significant clinical benefits 
and improved adherence. It can also decrease the inevitable negative 
consequences of polypharmacy, including medication burden and costs of 
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complex medication regimens.(114, 119) With appropriate cessation of 
medications in older adults, one has to consider factors such as the patient’s 
residual life expectancy, curtailing preventive treatments for those with a reduced 
survival prognosis, excluding medications with questionable evidence of 
effectiveness, and promoting the prescription of medications with favourable 
risk–benefit ratios.(88, 120) In 2003, Woodward proposed five principles of 
deprescribing: review all current medications, identify medications to be targeted 
for cessation, prepare a deprescribing regimen, discuss with patients and carers, 
and frequent review and support.(121)  
Scientific Evidence of Benefits of Deprescribing  
In a trial of 119 older adults, 332 medications (2.8 medications per patient on an 
average) were discontinued utilizing an algorithm, leading to a decrease in 
mortality by 24 per cent, a significant reduction in the referral rates to acute care 
facilities, and in health care costs.(120, 122) In a similar study conducted in Israel, 
58 per cent of medications were discontinued in older adults, with an 81 per cent 
success rate, without major untoward effects, and with almost 90 per cent of the 
patients reporting a holistic improvement in health.(120, 123) A systematic 
review conducted in Australia in 2008 observed that withdrawal of 
benzodiazepines and psychotropics diminished the number of falls, and improved 
cognition and psychomotor functioning in older adults.(124) Similarly, an RCT 
in the United Kingdom in 2009 demonstrated a decline in mortality when 
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antipsychotics were withdrawn in nursing home patients diagnosed with 
dementia.(125) In a relatively recent clinical trial, it was observed that individuals 
with a lower remaining life expectancy could safely discontinue statins, and the 
discontinuation was associated with a better quality of life and reduced associated 
medication costs.(126) The List of Evidence-baSed depreScribing for CHRONic 
patients (LESS-CHRON) criteria are the first explicit criteria to assist clinicians 
in deprescribing PIMs. Each of the 27 criteria consists of indications for which 
the medications are prescribed, clinical situations that offer an opportunity to de-
prescribe, clinical variables to be monitored, and the minimum time to follow the 
patient after deprescribing.(127) The Australian Deprescribing Network has 
developed the ‘Current medication, Elevated risk, Assess, Sort, Eliminate’ 
(CEASE) Deprescribing framework, a Deprescribing five step protocol, which 
includes taking a comprehensive medication history, identifying PIMs, 
determining whether the PIMs can be stopped, planning the withdrawal regimen 
(tapering where necessary), and the provision of monitoring, support, and 
documentation. It focuses on engaging patients throughout this sequence, with 
the aim of improving long-term health outcomes.(128) 
Barriers to Deprescribing  
For most prescribers, prescribing medications is easier than deprescribing, 
possibly because of the insufficient awareness of deprescribing.(129) A study 
conducted in Vancouver observed that family physicians were reluctant to de-
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prescribe the medications prescribed by another practitioner or specialist, and 
many physicians felt that they lacked the knowledge and skills to de-prescribe in 
a safe and effective manner in fear of initiating an adverse effect.(130) In another 
study, the physicians were not in favour of discontinuing medications because 
they usually followed the prescribing guidelines, and deprescribing often required 
discussing the patient’s limited life expectancy, which they found to be 
challenging.(131) A systematic review in 2013 explored the opinions of patients 
and observed that the fear of non-specific consequences makes patients reluctant 
to agree to cessation.(132) Sudden withdrawal of a medications could give rise to 
a physiological response, termed as “withdrawal reaction”, which could be 
prevented (or minimised) by tapering the dose before withdrawing a medication. 
Ceasing a particular medication may alter the pharmacokinetics and 
pharmacodynamics of other medications. There is a greater concern for 
negatively and irreversibly affecting the existing medical condition.(128) The 
common barriers to deprescribing include a lack of time and support, the anxiety 
of withdrawal reactions, and unfortunate experiences with the cessation of 
medications in the past. To overcome these barriers to deprescribing, it is 
important to educate the prescribers and patients about the problems associated 
with inappropriate prescribing and to develop guidelines for deprescribing.(129) 
The key is to minimise or discontinue the utilization of PIMS, commence or 
optimise the utilization of appropriate medications, account for a cautious dosage 
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of medications, consider the impact of renal function on medication clearance, 
and review any medication interactions during medication reviews.(133)  
2.4.2 Ongoing Research  
The Canadian Frailty Network, through the Networks of Centres of Excellence 
Program, is striving to improve the health care of older Canadians living with 
frailty, and as a part of its mandate, convened a stakeholders’ meeting to seek 
their perspectives on appropriate medication prescription. The priorities 
identified were:  
a) augmented efforts towards developing innovations focused on facilitating 
prescribing of appropriate medications, and/or deprescribing PIMs in older adults 
living with frailty 
b) facilitating research for developing or improving models that help pharmacists 
to be actively involved in the process of monitoring and assessing dispensing 
PIMs 
c) encouraging further research to study the values and preferences held by older 
adults living with frailty with respect to medication use.(134)  
Deprescribing is a field of continuing research, as clinicians recognise the 
significance of a parallel strategy to re-evaluate the prescription of medications. 
There is ongoing research to supplement the beneficial evidence for deprescribing 
by focusing on relevant patient outcomes such as a reduced falls, hospital 
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admissions, and mortality; improved sleep quality, cognitive function, 
independence in activities of daily living, and quality of life.(129) Deprescribing 
may be more beneficial than continuing intensive treatment regimens in older 
adults presenting with severe co-morbidities and in patients presenting with end-
stages of dementia or with a poor functional status. Researchers have been 
motivated to address de-intensification of medical therapy, which implies the 
discontinuation of medications in situations in which the potential problems 
outweigh the benefits.(135) Deprescribing has the potential to improve health-
outcomes; however, the clinical benefits and associated risks can be determined 
only after the development and validation of a systematic deprescribing process. 
An account of the decrease in mortality and morbidity will necessitate large 
RCTs, requiring hundreds or even thousands of participants in each arm, so the 
conduct of these trials may, unfortunately, not be feasible.(128) To achieve 
appropriate polypharmacy, deprescribing cannot be considered in isolation for 
optimising medications of older adults, as potentially inappropriate omissions 
have also been prevalent in this vulnerable population.(136) Importance should 
be given to integrating the deprescribing process with other interventions to 
reduce the prevalence of PIMs.  
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2.5 Strength of the study  
This review provides an updated overview of the benefits and limitations of the 
existing criteria for reducing inappropriate prescribing. The review also describes 
the potential methods useful in prescribing appropriate medications, and suggests 
deprescribing as a way forward.  
 
2.6 Limitation of the study 
The literature search was restricted to the inclusion of manuscripts published in 
English. In addition, the search terms may not be completely adequate, although 
the most-relevant criteria were included, and an additional manual search of the 
reference lists from the articles viewed was also performed. Most of the explicit 
criteria are based on the Beers criteria, which may have produced a bias. 
 
2.7 Conclusion  
Inappropriate prescribing of medications in older adults remains a major 
international health concern 
The Beers criteria and STOPP/START criteria were comprehensive, and were 
used most often in a number of studies in multiple countries. Other criteria in use 
were not comprehensive. A promising way forward to reduce PIMs is to 
encourage deprescribing, which is a positive, patient-centred intervention, and 
requires shared decision making, informed patient consent, close monitoring of 
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effects, and consideration of the cumulative risk from multiple medications 
caused by pharmacokinetic and pharmacodynamic interactions— the same 
prescribing principles that apply when the therapy is initiated. The development 
of evidence based prescribing guidelines and the inclusion of deprescribing 
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Parts of this chapter are based on the following peer-reviewed manuscript: 
Bala SS, Narayan SW, Nishtala PS. Potentially inappropriate medications in 
community-dwelling older adults undertaken as a comprehensive geriatric risk 
assessment. European Journal of Clinical Pharmacology. 2018;74(5):645-53. 
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responsibility for the integrity of the data and the accuracy of data analysis. P. 
N. designed the study. S. N. and S. B. performed the research. S. N. analyzed 
the data. P. N. contributed to the new methods or models. S. B. wrote the paper. 
All authors contributed to the data interpretation, critically commented on the 
manuscript for intellectual content, and approved the final manuscript. 
3.1 Context 
Optimal prescribing of medications in older adults is challenging, given that the 
approved doses of medications extrapolated from clinical trials may not be 
suitable for the whole geriatric population.(4) It is well known that several 
medications have to be prescribed with caution in older adults due to alterations 
in their pharmacokinetics and pharmacodynamics.(5) Older adults are prescribed 
a greater number of medications due to the presence of multiple comorbidities.(2) 
The utilization of a greater number of medications is an independent risk factor 
for increase in adverse events, medication interactions, hospital admissions, 
emergency department visits, prescribing cascades, high health-care costs, 
morbidity, and mortality in older people.(2, 3) 
Potentially inappropriate medications (PIMs) are defined as medications whose 
risks outweigh clinical benefits, particularly when there is a safer or more 
effective alternate therapy for the same condition.(6) Therefore, identifying 
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potentially inappropriate medications helps mitigate pharmacotherapy-related 
hazards in older adults. 
Several criteria have been developed globally for identifying PIMs. These criteria 
are either medication-based explicit criteria, such as the Beers criteria, or patient-
based implicit criteria, as the Medication Appropriateness Index.(137)The Beers 
criteria is a comprehensive screening tool that has been validated by a systematic 
literature review and evaluated by a Delphi consensus. It has shown good 
productive validity in different settings.(138)  
Studies in NZ have found that individuals over 65 years of age are the most 
frequent consumers of medications, and the prevalence of polypharmacy and 
hyper polypharmacy is high and increasing in this vulnerable population.(139) 
 
3.2 Objectives 
The primary aim of this study was to identify PIMs exposure, applying the 2012 
and 2015 Beers criteria, in community-dwelling older adults who had undertaken 
a comprehensive geriatric risk assessment. 
The specific objectives were as follows: 
1. To examine the prevalence of exposure to PIMs, the most common PIMs 
prescribed, the prevalence of prescription of PIMs that may potentially exacerbate 
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existing disease or syndrome in older adults of NZ, and medications to be used 
with caution, applying the 2012 and updated 2015 Beers criteria.  
2. To examine the prevalence of potential clinically important non-anti-infective 
medication interactions that should be avoided in older adults, utilizing the 
updated 2015 Beers criteria. 
 
3.3 Methodology 
The study was approved by the Human Ethics Committee, University of Otago, 
NZ (ethical approval number 15/CEN/45/AM02) (Appendix). 
3.3.1 The study population 
Our retrospective study encompassed 70,479 community-dwelling individuals, 
aged 65 years and older, living in NZ. The study population included all 
individuals who received at least one prescription medication between 2012 and 
2015. 
3.3.2 Data source 
The following extracts were obtained from the Ministry of Health to undertake 
this study: 
1. Pharmaceutical Claims Data Mart (PHARMS) extract files (2012 to 2015)  
2. interRAI-HC: Individuals who had their first interRAI-HC assessment between 
1 September 2012 and 31 October 2015 were included in the study.  
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The clinical assessments were made available from cross-matched data from the 
interRAI-HC. The interRAI-HC assessments contained information on 
demographic (including ethnicity), social, and clinical diagnosis. The scales used 
in the interRAI-HC assessments are based on internationally validated 
performance scales. For example, the cognitive performance scale is based on the 
Minimum Data Set Cognitive Performance Scale.(42) 
3.3.3 PIMs exposure 
PIMs were identified using the 2012 and updated 2015 Beers criteria.(21, 138) 
Exposure to PIMs was considered if an individual was dispensed one or more 
potentially inappropriate medications for any duration during the study period. A 
list of medications not available in NZ or not subsidized is given in Appendix 1, 
and these were excluded from the study. The 2012 Beers criteria were applied to 
the data (N = 53,911) from July 2012 to December 2014, and the 2015 Beers 
criteria were applied to the data from January to October 2015 (N = 16,568). Data 
was digitized according to medications prescribed 90 days before assessment, 90 
days after assessment, and 90 to 180 days after assessment, allowing for the time-
varying effect of prescribing. Data cleaning, coding and analysis were automated 
through the SPSS software and completed by Narayan S and Bala S. The 
processes for classification were completed by all the authors as a team. 
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3.3.4 Statistical analysis 
The “STrengthening the Reporting of OBservational studies in Epidemiology” 
(STROBE) guidelines (www.strobe-statement.org) (140) were followed to report 
the analysis. Age of the individuals was stratified as 65–74 years, 75–84 
years, 85–94 years, and over 95 years. All descriptive statistical analysis were 
conducted using IBM SPSS version 24.(141) p< 0.05 was regarded as statistically 
significant. The Wilson method for calculating confidence intervals for 
proportions (142) was utilized to compare the PIMs exposure as a time-varying 
exposure, digitized into 90 days, at a significance of p < 0.001. The chi-square 
test was used to analyse nominal/categorical data. 
 
3.4 Results 
The study used data extracted from the matched interRAI-HC-PHARMS dataset, 
for the time period 2012 to 2015, to identify the prevalence of exposure to PIMs 
in older adults of NZ. In total, 70,479 individuals aged 65 years and older were 
studied, of which females constituted 61.3% in 2012–2014 and 60.1% in 2015. 
The mean age of the individuals was 83.7 (± 7.4) years in 2012–2014 and 82.35 
(± 7.6) years in 2015. The sociodemographic characteristics of the study 
population are depicted in Table 3.1. The prevalence of prescribing PIMs 90 days 
before and after treatment was 2.17 and 6.92% for 2012–2014, and 7.13 and 
24.7% for 2015, respectively. The percent change in PIMs in 2012–2014 and 
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2015 after 90 days of assessment was 4.70% (confidence interval (CI) 4.50%, 
5.00%, p < 0.001) and 17.60% (95% CI 16.80%, 18.30%, p < 0.001), respectively 
(Table 3.7). The average number of medications dispensed was 2.47 in 2012–
2014, and 2.41 in 2015, evaluated 90 days before assessment (Table 3.2). As 
illustrated in Tables 3.3, and 3.4, the exposure to PIMs 90 days before assessment 
was highest in individuals aged 95 years and over (3.21% in 2012–2014, and 
8.69% in 2015), and was higher in males (2.80% in 2012–2014, and 7.30% in 
2015). Data analysis was carried out on all ethnicities; however, the data on NZ 
Europeans and Māori were specifically reported, as they constitute the largest 
ethnicities in NZ.(143) In 2012–2014, 2.2% of NZ Europeans and 2% of the 
Māori population were prescribed PIMs. In 2015, 7% of NZ Europeans and 9.5% 
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Table 3.1 Characteristics of the study population (N = 70,479) 
  Total Percent 
Age 
 65–74 12,151 17.2 
 75–84 28,976 41.1 
 85–94 27,022 38.3 
 95+ 2330 3.3 
Sex 
 Female 43,008 61 
 Male 27,467 39 
Ethnicity 
 NZ European 62,340 88.5 
 Māori 3801 5.4 
 Other 4338 6.2 
Marital status 
 Married 27,375 38.8 
 Other 43,104 61.2 
Living arrangements 
 Alone 34,931 49.6 
 Spouse only 22,328 31.7 
 Others 13,220 18.8 
Cognitive impairment 
 None/minimal 37,007 52.5 
 Mild 21,884 31.1 
 Moderate 7544 10.7 
 Severe 4042 5.7 
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 No 60,374 85.7 
 Yes 10,105 14.3 
Depression 
 No 61,745 87.6 
 Yes 8732 12.4 
Schizophrenia 
 No 69,966 99.3 
 Yes 511 0.7 
Parkinson’s disease 
 No 67,789 96.2 
 Yes 2688 3.8 
Heart failure 
 No 58,106 82.4 
 Yes 12,371 17.6 
Cancer 
 No 59,872 85 
 Yes 10,605 15 
Stroke 
 No 58,170 82.5 
 Yes 12,309 17.5 
Chronic obstructive pulmonary disease 
 No 59,174 84 
 Yes 11,305 16 
Diabetes 
 No 55,925 79.3 
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 Yes 14,554 20.7 
Coronary heart disease 
 No 47,989 68.1 
 Yes 22,490 31.9 
Hemiplegia 
 No 67,970 96.4 
 Yes 2509 3.6 
Hip fracture 
 No 69,173 98.1 
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Table 3.2: Summary of the findings in the interRAI-HC dataset according to the 2012 
and 2015 Beers criteria (90 days before assessment) 
  
 2012-2014 2015 
Average number of medications for each patient 2.47 2.41 
Average number of PIMs 0.04 0.19 
Classification of most common PIMs prescribed 
 Medications of the central nervous system (%) 1.45 3.70 
 Medications of the gastrointestinal system (%) 0.79 5.20 
Medications prescribed for pain (%) 0.76 3.44 
Syndromes/diseases where the PIMs prescribed may exacerbate the medication-disease interactions 
 Falls (%) 1.97 6.90 
 Incontinence (%) 5.60 1.47 
 Heart failure (%) 0.80 3.18 
 Constipation (%) 2.30 NA 
 Dementia (%) 1.35 3.60 
Medications to be used with caution in older adults 
 Antipsychotics (%) 0.68 1.97 
 Tricyclic antidepressants (%) 0.47 1.69 
 Selective serotonin reuptake inhibitors (%) 0.44 1.37 
Potentially important non-anti-infective medication interactions that should be avoided in older adults 
 Opioid receptor agonist analgesics and more than 2 CNS-active medications (%) NA 4.96 
 More than 1 anticholinergic medication prescribed to a patient (%) NA 3.25 
 Benzodiazepines and non-benzodiazepines, benzodiazepine receptor agonist hypnotics, 
and more than 2 CNS-active medications (%) 
NA 2.77 
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Table 3.3: Classification of PIMs according to gender and ethnicity (90 days before assessment) 
 
  Males (%) Females (%) NZ European (%) Māori (%) 
2012–2014 
 Total 20,864 (38.70) 33,044 (61.30) 47,701 (88.40) 2844 (5.27) 
 Exposure to PIMs 589 (2.80) 582 (1.70) 1046 (2.20) 57 (2.00) 
2015 
 Total 6603 (39.8) 9964 (60.1) 14,639 (88.30) 957 (5.80) 
 Exposure to PIMs 485 (7.30) 697 (7.00) 1021 (7.00) 91 (9.50) 
 
Table 3.4: Classification of PIMs according to age of the patients 
 
  65–74 years (%) 75–84 years (%) 85–94 years (%) 95+ years (95%) 
2012–2014 
 Total 9103 (16.9) 22,200 (41.2) 20,830 (38.6) 1778 (3.3) 
 Exposure to PIMs 209 (2.29) 459 (2.06) 446 (2.14) 57 (3.21) 
2015 
 Total 3048 (18.40) 6776 (40.90) 6192 (37.40) 552 (3.30) 
 Exposure to PIMs 230 (7.54) 479 (7.07) 425 (6.86) 48 (8.69) 
 
The summary findings of the study are illustrated in Tables 3.2-3.7. The average 
number of PIMs prescribed for an individual 90 days before assessment was 0.04 
in 2012–2014 and 0.19 in 2015 (Table 3.2). In total, 2.17% individuals were 
prescribed PIMs in 2012–2014, and 7.13% in 2015, 90 days before assessment 
(Table 3.7). In 2012-2014, the maximum number of PIMs were prescribed 90 
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days after assessment, most of which belonged to the therapeutic class of the 
central nervous system (CNS) (Table 3.5).  
A greater number of PIMs were prescribed in the time slices after assessment for 
the year 2015, and most of which belonged to the therapeutic class of the 
gastrointestinal (GI) system (Table 3.6). There has been a decline in the 
prevalence of PIMs in 2012–2014 in the time period of 90–180 days after 
assessment (4.4%) compared to 90 days after assessments (6.92%) (Table 3.5). 
However, the prevalence of PIMs in 2015 remained unchanged after 90 days and 
90–180 days of assessments (24.6%) (Table 3.6). 
In 2012–2014, the medications which were contraindicated in patients presenting 
with urinary incontinence and constipation, featured commonly among the 
medications to be avoided for older adults with specific diseases or syndromes, 
as depicted in Table 3.5. In 2015, the medications which were contraindicated in 
falls and dementia, were among the most commonly prescribed medications to be 
avoided for older adults with specific diseases or syndromes, as shown in Table 
3.6. Among the medications to be prescribed with caution in older adults, 
antipsychotics were prescribed most often in 2012–2014 (Table 3.5), and 
diuretics topped the list in 2015 (Table 3.6). Of the potentially clinically 
important non-anti-infective medication interactions to be avoided, most of the 
interactions were observed when opioid medications were prescribed with more 
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than two CNS-active medications, and when more than one anticholinergic 
medications were prescribed to the same patient (Table 3.6).  
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Table 3.5:  Numeric values for data analysis utilizing the 2012 American Geriatrics Society Beers 
Criteria for the year 2012-2014 (according to the date of assessment) 
 
Number of Potentially Inappropriate Medications (PIMs) prescribed 
Number of 
PIMs 


















































Potentially inappropriate medications prescribed according to the therapeutic class 
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*GIT-Gastro-intestinal system, CNS-Central nervous system, CVS-Cardiovascular system, HF-Heart Failure, SNRI- Serotonin and norepinephrine reuptake inhibitors, 
SSRI- Selective Serotonin Reuptake Inhibitors, TCA-Tricyclic Antidepressants, AP-Antipsychotics, AI-Anti-infectives, Carb-Carboplatin, VD-Vasodilators, AC-
Anticholinergics, At-Anti-thrombotics 











































































Medications to be prescribed with caution 
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Table 3.6: Numeric values for data analysis utilizing the 2015 American Geriatrics Society Beers Criteria for the 
year 2015 (according to the date of assessment)  
 
Number (%) of Potentially Inappropriate Medications (PIMs) prescribed 
Number of PIMs 0 1 2 3 4 5 6 7 




















































PIMs prescribed to the study population according to the therapeutic class 
 Pain GIT Endocrine CNS AI AC CVS Genitourinary 
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*GIT-Gastro-intestinal system, CNS-Central nervous system, CVS-Cardiovascular system, HF-Heart failure, UI- Urinary Incontinence, SNRI- Serotonin and norepinephrine reuptake inhibitors, 
SSRI- Selective Serotonin Reuptake Inhibitors, TCA-Tricyclic Antidepressants, BZD-Benzodiazepines and non-benzodiazepines, benzodiazepine receptor agonist hypnotics, ACE-I-Angiotensin 
converting enzyme inhibitors, Loop-Loop Diuretics, CS-Corticosteroid, AP-Antipsychotics, AI-Anti-infectives, CP-Carboplatin, CZ-Carbamazepine, MZ-Mirtazapine, AC-Anticholinergics, AD-
Anti-depressants 
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3.5 Discussion  
Older adults represent a significant proportion of the population in NZ; the 
majority of whom present with multiple chronic medical conditions, and 
subsequently, the number of medications prescribed continues to rise in this 
vulnerable population.(144) A study conducted previously in NZ has shown a 
significant increase in polypharmacy and hyperpolypharmacy in the past 
decade.(139) Consequent to the increase in polypharmacy, the number of PIMs 
Year Study population PIMs % 95% CI, p-value 
 2012-2014       
before 90 days 53,911 1,171 (2.17) 4.70%, 95% CI 4.50%, 5.00%, p<0.001  
After 90 days  53,911 3,729 (6.92)  
        
before 90 days 53,911 1,171 (2.17) 2.10%, 95% CI 1.9%, 2.30%, p<0.001  
90-180 days 53,911 2,321 (4.3)  
    
 2015       
before 90 days 16,568 1,182 (7.13) 17.60%, 95% CI 16.80%, 18.30%, p<0.001  
After 90 days  16,568 4,091 (24.7) 
 
        
before 90 days 16,568 1,182 (7.13) 17.60%, 95% CI 16.80%, 18.30%, p<0.001  
90-180 days 16,568 4,091 (24.6) 
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being prescribed has shown to increase over time in older adults.(12) Our unique 
study examines the prevalence of PIMs for the first time in NZ in a high-risk 
population who had undertaken a comprehensive geriatric risk assessment. The 
prevalence of PIMs was 2.17% in 2012–2014, and 7.13% in 2015, when 
evaluated 90 days before assessment. Exposure to PIMs was highest in 
individuals aged over 95 years and in males. The average number of PIMs for 
each patient was 0.04 in the period 2012–2014, and 0.19 in 2015. The majority 
of PIMs prescribed belonged to the therapeutic class of the CNS and the GI 
systems. 
In a study conducted in community-dwelling older adults in NZ (13), 42.7% 
individuals were prescribed at least one PIM according to the 2012 Beers criteria, 
which is much higher than the PIMs detected in our study (2.17% in 2012–2014, 
and 7.13% in 2015, before 90 days). A primary reason for the difference could be 
that the geriatric risk assessments are conducted in older individuals living in the 
community requiring complex care needs, whereas the study conducted by 
Nishtala et al. (N = 316) identified PIMs in a surveyed population of older adults 
living in the community. For this study, we have only considered a 90-day period 
to estimate the prevalence of PIMs. The annual prevalence could be much higher 
and comparable to other studies that have examined the prevalence of PIMs in 
the general population. The prevalence of PIMs was 40.9% in a similar 
population-level study (N = 537,387) conducted in older adults in NZ, utilizing 
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the 2012 Beers criteria.(14) The study used data extracted from the matched 
National Minimum Dataset (NMDS)-PHARMS dataset for the year 2011. The 
most common PIMs dispensed to their study population were medications 
belonging to the CNS, a finding analogous to our study. The primary reason for 
this could be a dramatic increase in the number of CNS-active medications 
prescribed for older adults in the past decade.(145) Similarly, in a recent study 
conducted in Australia, it was observed that there is a high rate of prescription of 
medications acting on the CNS among older adults.(146) 
In the current study, the prescription of PIMs was observed to be highest in 
individuals aged over 95 years, similar to the findings of the study by San-José et 
al. (147), in which majority of PIMs were prescribed to the oldest old patients. A 
high prevalence of PIMs could be attributed to the significant multi-morbidity in 
this cohort requiring complex care. Males were exposed to a higher number of 
PIMs in our study, in contrast to the observations by Narayan and Nishtala, in 
which the PIMs were more prevalent in females.(14) The disparity could be due 
to differences in the comorbidities captured in the datasets. The older NZ 
Europeans and Māori ethnic group were prescribed a higher percentage of PIMs 
in 2015 compared to 2012–2014, 90 days before assessment. Narayan and 
Nishtala (14) have reported a higher prevalence of PIMs in the European 
population of NZ. Nishtala and Salahudeen have reported that the prevalence of 
PIMs is high and increasing over recent years in Māori but is less compared to 
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NZ Europeans.(139) There is also evidence to show that the Māori group receive 
fewer prescriptions compared to the non-Māori group of individuals.(148) 
Medications that could have potentially exacerbated the existing disease or 
syndromes were primarily prescribed for the treatment of incontinence (5.6%) 
and constipation (2.3%) for 2012–2014 (90 days before assessment). These 
results are similar to those of the study conducted by Narayan and Nishtala, in 
which a greater proportion of PIMs were observed for the treatment of 
incontinence and constipation.(14) Furthermore, in the year 2015 (90 days before 
assessment), medications that could have potentially exacerbated the existing 
disease or syndromes were those prescribed for the treatment of falls (6.9%) and 
dementia (3.6%), similar to the findings of a study conducted in Pennsylvania in 
2015.(149) There is a proportional increase in the incidence of incontinence, 
constipation, falls, and dementia as one ages.(150-153) 
Various studies detected a high prevalence of PIMs prescription in hospitalized 
and elderly patients, and recipients of home health-care services in Nigeria, 
Taiwan, and India, utilizing the Beers criteria of 2012.(137, 154, 155) A study 
conducted in Spain, a year before and after the intervention of an educational 
seminar on Beers criteria, showed no significant difference in the potentially 
inappropriate prescriptions.(156) 
The prevalence of PIMs in the current study is mainly influenced by our study 
population, which included older adults with complex care needs, compared to 
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the general population of older adults in the other international studies. We 
digitized the PIM exposure in 90-day slices, and hence, this may not reflect the 
cumulative PIM exposure during the study period. The variability in PIM 
exposure between studies can be attributed to the research designs (retrospective 
or prospective cohort, cross-sectional designs, reporting of point prevalence, or 
annual PIMs prevalence), different versions of the Beers criteria applied, 
prescribing patterns based on cost and locally recommended guidelines and 
formularies, and characteristics of the study population and settings (primary 
care, secondary care, continuing care). 
The involvement of pharmacists in pharmaceutical care and strategies focusing 
on deprescribing are just two examples of initiatives that have been proposed in 
NZ to help reduce the prescription of PIMs..(157, 158) Individualized assessment 
that reviews the necessity for continuing each medication helps simplify 
treatment regimens and reduces the potential for adverse reactions. While 
withdrawing a prescribed medication, several factors must be considered, such as 
clinical indication and benefit of treatment, appropriateness of the regimen, 
duration of use, patient adherence, and the prescribing cascade.(158) The review 
and modification of a patient’s medication regimen should be conducted by a 
multidisciplinary team comprising a pharmacist, physician, and nurse. There is 
also an overwhelming need for efficient education in geriatric prescribing through 
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an integrated approach involving the physician, pharmacologist, pharmacist, and 
patient.(159) 
The Beers criteria are derived from expert opinions, published reviews, consensus 
techniques, and seldom require a clinical judgement for its application.(138) The 
2015 Beers criteria appear to be a more comprehensive guide to medication safety 
in older adults, compared to the 2012 Beers criteria, since the modifications have 
been made according to current clinical prescribing practices. The results are 
reflected in our study, noting that the updated 2015 Beers criteria have captured 
more PIMs (7.13%), compared to the 2012 Beers criteria (2.17%). In the 2015 
Beers criteria, there has been an inclusion of avoiding  desmopressin for the 
treatment of nocturia or nocturnal polyuria because of the high risk of 
hyponatremia; avoidance of the use of proton-pump inhibitors beyond 8 weeks 
without justification; avoiding non-benzodiazepine, benzodiazepine receptor 
agonist hypnotics in individuals with dementia or cognitive impairment; the 
addition of opioids to the list of CNS medications that should be avoided in 
individuals with a history of falls or fractures; and avoidance of antipsychotics as 
a first-line treatment of delirium.(21) The 2015 Beers criteria utilize a more 
widespread systematic review and grading of evidence, since they eliminate many 
medications that are no longer used in clinical practice.(160) Separate guidelines 
on avoiding thirteen combinations of medications known to cause harmful 
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medication interactions has also been supplemented in the 2015 Beers 
criteria.(21) 
 
3.6 Strength of the study 
Because of the wide prescription coverage in this population, selection bias may 
have been eliminated. A major strength of the study is that, for the first time, a 
nationwide database of a comprehensive geriatric assessment was set up to 
capture a suite of clinical and sociodemographic data. The interRAI-HC 
assessment allows for comparing data on residents with similar needs within a 
facility or within a chain of facilities, so a standardized best practice approach to 
providing care can be used. The availability of multiple diagnoses in the 
interRAI-HC assessments enabled the accurate identification of PIMs according 
to the 2012 and 2015 Beers criteria. 
 
3.7 Limitations 
Not all medications (41) listed in the Beers criteria were available in NZ or funded 
by PHARMAC (Pharmaceutical Management Agency). Potential bias such as the 
use of the cross sectional study design presents as an inherent limitation and can 
limit the applicability of the findings. Further limitations were the unavailability 
of laboratory data, such as creatinine clearance (CrCl) values, due to which the 
medications that should have been avoided or have their dosage reduced to 
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varying levels of kidney function in older adults according to the 2015 Beers 
criteria, have not been considered in the study. The study might not be applicable 
to other countries because of variances in health systems, prescribing guidelines, 
and the cost of medications, as they influence prescribing patterns. In addition, 
the population under study is a high-risk population requiring complex care 
needs, different from other study populations. The updated criteria were applied 
retrospectively, and it is possible that certain aspects of the criteria might not have 
been applicable and/or been considered by prescribers during the study period. It 
was hard to ascertain if aspirin was prescribed for primary prevention of cardiac 
events, and hence, aspirin was not considered as one of the medications to be used 
with caution for our study. We excluded the list of non-anti-infective medications 
that should be avoided or have their dosage reduced with varying levels of kidney 
function in older adults (Beers 2015 criteria), since serum creatinine values were 
not available to estimate the renal function. 
Since data was unavailable to identify the exact number of individuals prescribed 
PIMs based on CrCl, individuals were stratified into age groups, assuming that 
individuals > 85 years would have a lower CrCl for nitrofurantoin and 
spironolactone.(14) The dispensing of antipsychotics for short-term use as an 
antiemetic or for behavioural problems of dementia could not be ascertained, and 
these were excluded from the analysis. Additionally, diagnoses including atrial 
fibrillation, recently decompensated heart failure, hypogonadism, removal of the 
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pituitary gland, gastroparesis, Barrett’s esophagitis, pathological hypersecretory 
condition, agitation, delirium, peptic ulcers, chronic kidney disease, lower urinary 
tract symptoms, benign prostatic hypertrophy, and epilepsy could not be 
identified from the interRAI-HC assessments, and were excluded from the 
analysis. Furthermore, we could not identify a diagnosis of hypertension from the 
interRAI-HC assessments; hence, the indication for clonidine or peripheral alpha 
blockers as antihypertensive agents could not be confirmed. In addition, data was 
unavailable to identify specific conditions for prescriptions with estrogens. 
 
3.8 Conclusion 
The diligent use of the Beers criteria can alert clinicians to improve prescribing 
in this high-risk population vulnerable to adverse events. However, it is important 
to note that in spite of their widespread applicability across countries and settings 
since 1991, prescribing of PIMs continues to pose a challenge in older adults. 
Despite these limitations, incorporation of the Beers criteria as an indicator to 
assess the quality of prescribing in older adults has the potential to reduce adverse 
outcomes and costs associated with inappropriate prescribing. The high 
prevalence of PIMs in our population with complex care needs may suggest that 
a comprehensive medication review may not be a focus of these geriatric 
assessments. The primary focus of these assessments is on functional, cognitive, 
and quality of life domains. Our findings highlight that interRAI-HC assessments 
Chapter 3: Prevalence of prescribing potentially inappropriate medications in community dwelling 
older adults of New Zealand                                                
                                                                                                                                                           
75 
 
provide a significant opportunity to re-evaluate prescribing in a cohort of 
vulnerable older adults requiring complex care needs. In this study, the 
prevalence of PIMs was examined at the first geriatric assessment. Further studies 
are warranted to examine the impact of repeated geriatric assessments on the 
prevalence of PIMs, and to identify factors associated with inappropriate 
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4.1 Context  
4.1.1 Prescribing patterns in older adults in New Zealand (NZ) 
Optimal prescribing of numerous medications in older adults is often debated and 
difficult to achieve, and subsequently there is a high prevalence of prescription 
of inappropriate medications.(161) Several characteristics of aging (alterations in 
pharmacokinetics and pharmacodynamics, frailty, geriatric syndromes, and 
multiple concomitant illnesses) influence prescribing in older adults.(2) 
Potentially inappropriate medications (PIMs) are most commonly identified by 
criterion-based explicit screening tools, of which the Beers Criteria are used 
frequently.(162) Pharmacopeidemiological studies conducted in NZ have 
reported that 42.7% of the community-dwelling older adults were prescribed 
PIMs, and 40.9% individuals living in residential aged-care facilities were 
prescribed PIMs.(13, 14)  
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A few studies (163, 164) have focused on identifying predictors of prescribing 
PIMs in older adults in various settings; however, the evidence for factors 
influencing the prescription of PIMs in home-based older adults with complex 
care needs is limited.(165) Consequent to the higher prevalence of prescription 
of PIMs in community dwelling older adults in NZ (166), it is important to 
identify the associated factors and to target interventions to reduce their 
occurrence.(167) The comprehensive geriatric risk assessment in residential care 
homes by utilizing the interRAI-HC (International Resident Assessment 
Instrument-Home care) tool has been mandated in NZ since 2015 for all 




To identify factors associated with the prescription of PIMs in older adults who 
had undertaken a comprehensive geriatric risk assessment. 
 
4.3 Methodology 
We obtained the approval of the institutional review board: Ethical approval 
number 15/CEN/45/AM02.  
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4.3.1 Data source 
The retrospectively conducted cross-sectional study utilized the comprehensive 
geriatric assessment, interRAI-HC-PHARMS (Pharmaceutical Claims Data 
Mart) matched dataset for extracting anonymous data of all adults aged 65 years 
and over, who were dispensed at least one prescription medication between 
January–October 2015. The interRAI-HC data and PHARMS data are described 
in detail in the introduction of the thesis. For this study, where an individual had 
undertaken multiple geriatric risk assessments in 2015, we only utilized the first 
comprehensive geriatric risk assessment. The PHARMS extract files for 2015 
furnished information pertaining to the prescription claims prepared by 
community pharmacists and funded by PHARMAC (Pharmaceutical 
management agency).(168) 
4.3.2 Study population 
In total, 16,568 community-dwelling individuals, aged 65 years and older, living 
in NZ, who had undertaken the first comprehensive geriatric risk assessment and 
had received one or more prescription medications in 2015, were included. 
4.3.3 PIMs exposure 
Individuals who were prescribed at least one potentially inappropriate medication 
in 2015 according to the 2015 Beers criteria (21), were classified as those 
prescribed PIMs. 
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A literature review was performed to determine the most common factors 
influencing the prescribing of PIMs. The individuals were categorized in age 
groups of 65–74 years, 75–84 years, 85–94 years, and over 95 years. Data 
analysis was performed for all ethnicities, with specific emphasis for NZ 
Europeans and Maori, as they are in majority in NZ.(14)  
Based on the literature review, a number of explanatory variables were tested for 
their influence on prescribing trends of PIMs, and these included: 
a. Sociodemographic(167, 169, 170):Age, sex, ethnicity, marital status, alcohol 
intake, smoking, living arrangements, number of medications. 
b. Clinical(171-178): Activities of daily living, self-reported health, 
hospitalization, dementia, insomnia, depression, anxiety, hemiplegia, Parkinson’s 
disease, stroke, coronary heart disease (CHD), congestive cardiac failure (CCF), 
diabetes, chronic obstructive pulmonary disease (COPD), bowel incontinence, 
urinary incontinence, urinary tract infection, falls, fracture, cancer.  
Although the 2015 Beers criteria excludes patients requiring palliative care, we 
have included cancer as a risk factor associated with the prescription of PIMs. 
4.3.5 Statistical analysis 
The STrengthing the Reporting of Observational studies in Epidemiology 
(STROBE) guidelines (www.strobe-statement.org) was used to report the 
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analysis conducted for this study (Appendix 2.1). A multinomial logistic 
regression model was used to measure the relationship between PIMs prescription 
and all the explanatory variables. The outcome variables were prescription of 1–
2 PIMs and >3 PIMs. Individuals not prescribed PIMs (nil PIMs) formed the 
reference group. Individuals with a diagnosis of any of the clinical ailments 
mentioned above were flagged as a binary variable; those with the diseased 
condition were coded as 1, the coding for no ailments was 0. The explanatory 
variables were tested for multi-collinearity. 
Model assumptions were tested using the Hosmer Lemeshow goodness-of-fit test. 
All descriptive statistics were conducted using IBM SPSS version 24.(141) 




The InterRAI-HC information and prescription use data for 16,568 individuals 
aged 65 years and older were extracted; of these, females constituted 60.1% 
(9,964). The mean age of the individuals was 82.35 (± 7.6) years. Table 4.1 
illustrates the sociodemographic variables of the population studied, and Table 
4.2 displays the association of PIMs with the investigated variables according to 
the corresponding 95% confidence interval (CI) (p < 0.05). We have 
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independently considered the associations of 1–2 PIMs and >3 PIMs for each 
individual. 
4.4.1 Sociodemographic factors 
Males were prescribed a slightly higher number of PIMs than females (43.1% for 
1–2 PIMs and 48% for >3 PIMs); individuals over 75 years of age were less likely 
to be prescribed PIMs (35.6% for 1–2 PIMs and 57.7% for >3 PIMs), compared 
to individuals aged 65–75 years, and the Maori ethnic group were less likely to 
be prescribed PIMs (47.5% for 1–2 PIMs, 41.3% for >3PIMs) compared to the 
NZ Europeans (43.1% for 1–2 PIMs and 48.9% for >3 PIMs). In addition, 
individuals who were prescribed a greater number of medications were more 
likely to be prescribed PIMs [aOR (Adjusted Odds Ratio) = 1.12, CI = 1.11–1.13 
for 1–2 PIMs, and aOR 1.22, CI = 1.21–1.23 for >3 PIMs), compared to 
individuals prescribed a single medication (Table 4.2). 
4.4.2 Clinical factors associated with the prescription of 1–2 PIMs 
With respect to the activities of daily living, the individuals who were being 
supervised (aOR = 0.82, CI = 0.68–0.98), who required extensive care (help 
throughout the task, but performed 50% or more of the task on their own) (aOR 
= 0.74, CI = 0.56–0.97), and who required maximal care (help throughout the 
task, but performed less than 50% of the task on their own) (aOR = 0.67, CI = 
0.47–0.95) were less likely to be prescribed 1–2 PIMs, compared to individuals 
who were independent in their self-performance and capacity. Individuals who 
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reported good self-health (aOR = 0.74, CI = 0.56–0.98) were less likely to be 
prescribed 1–2 PIMs compared to individuals who reported poor self-health. 
Individuals diagnosed with diabetes (aOR = 0.75, CI = 0.63–0.89) were less 
probable to be prescribed 1–2 PIMs compared to individuals not diagnosed with 
diabetes. Individuals diagnosed with insomnia (aOR = 1.44, CI = 1.23–1.69) were 
more likely to be prescribed 1–2 PIMs, compared to individuals not diagnosed 
with insomnia. Individuals who were diagnosed with stroke (aOR = 0.69, 
CI = 0.58–0.52) or COPD (aOR = 0.79, CI = 0.65–0.96) had a lesser probability 
of being prescribed 1–2 PIMs, compared to the individuals who were not 
diagnosed with either of the diseases. 
4.4.3 Clinical factors associated with ≥3 PIMs 
Individuals who reported excellent (aOR = 0.62, CI = 0.41–0.93) and good self-
health (aOR = 0.63, CI = 0.47–0.85) were less expected to be prescribed ≥3 PIMs 
compared to individuals who reported poor self-health. Individuals who were 
hospitalized in the last 90 days (aOR = 1.19, CI = 1.02–1.38) were more likely to 
be prescribed ≥3 PIMs, compared to individuals who had not undergone 
hospitalization in the last 90 days. Individuals diagnosed with cancer 
(aOR = 1.35, CI = 1.11–1.66) were more probable to be prescribed ≥3 PIMs, 
compared to individuals with no diagnosis of cancer. Individuals with the 
diagnosis of diabetes (aOR = 0.65, CI = 0.54–0.77) had a lesser likelihood of 
being prescribed ≥3 PIMs, compared to individuals not diagnosed with diabetes. 
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Individuals diagnosed with dementia (aOR = 1.26, CI = 1.05–1.51) were more 
likely to be prescribed ≥3 PIMs, compared to individuals not diagnosed with 
dementia. Individuals with the diagnosis of insomnia (aOR = 1.80, CI = 1.53–
2.11) had a greater likelihood of being prescribed ≥3 PIMs, compared to 
individuals not diagnosed with insomnia. Individuals diagnosed with anxiety 
(aOR = 1.77, CI = 1.32–2.36) and depression (aOR = 1.68, CI = 1.28–2.19) had 
higher odds of being prescribed ≥3 PIMs, compared to individuals who were not 
diagnosed with either of the conditions. Individuals diagnosed with CCF 
(aOR = 0.76, CI = 0.62–0.93) were less expected to be prescribed ≥3 PIMs, 
compared to individuals not diagnosed with CCF. Similarly, individuals 
diagnosed with stroke (aOR = 0.56, CI = 0.47–0.67) or COPD (aOR = 0.51, 
CI = 0.41–0.63) were less likely to be prescribed ≥3 PIMs, compared to 
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Table 4.1 Characteristics of the study population (n =16,568) 
  
 N (%) 
Age (years) 
65-74 3,048 (18.4) 
75-84 6,776 (40.9) 
85-94 6,192 (37.4) 
95+ 552 (3.3) 
Sex a 
Female 9,964 (60.1) 
Male 6,603 (39.9) 
Ethnicity 
European 14,639 (88.4) 
Māori 957 (5.8) 
Other 972 (5.9) 
Marital status 
Married 6,607 (39.9) 
Other 9,961 (60.1) 
Alcohol   
No 13,225 (79.8) 
Yes 3,343 (20.2) 
Smoking   
No 15,653 (94.5) 
Yes 915 (5.5) 
Living arrangements 
Alone 8,019 (48.4) 
Spouse only 5,447 (32.9) 
Other 1,292 (7.8) 
With child b 1,810 (10.9) 
Activities of daily livingc 
Independent 9,985 (60.3) 
Supervision 2,143 (12.9) 
Limited 1,782 (10.8) 
Extensive 1,046 (6.3) 
Maximal 730 (4.4) 
Dependentd 880 (5.3) 
Self-reported health 
Poor 1925 (11.6) 
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Excellent 522 (3.2) 
Good 6,806 (41.1) 
Fair 5,695 (34.4) 
Could not  respond 1,620 (9.8) 
Hospitalisation 
No hospitalisatione 8,602 (51.9) 
Other 7,966 (48.1) 
Cancer 
No 13,706 (82.7) 
Yes 2,862 (17.3) 
Dementia 
No 14,378 (86.8) 
Yes 2,190 (13.2) 
Insomnia 
No 11,795 (71.2) 
Yes 4,773 (28.8) 
Depression 
No 14,653 (88.4) 
Yes 1,915 (11.6) 
Bipolar  
No                         16,404 (99.0) 
Yes 164 (1.0) 
Anxiety 
No 15,046 (90.8) 
Yes 1,522 (9.2) 
Schizophrenia 
No 16,441 (99.2) 
Yes 127 (0.8) 
Hemiplegia 
No 16,148 (97.5) 
Yes 420 (2.5) 
Parkinson’s Disease 
  No 16,014 (96.7) 
  Yes                               554 (3.3) 
Stroke 
   No 13,895 (83.9) 
  Yes                                             2,673 (16.1) 
Coronary heart disease 
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  No 11,670 (70.4) 
 Yes 4,898        (29.6) 
Congestive-cardiac failure                  
  No                                      13,895       (83.9) 
 Yes                                2,673             (16.1) 
Diabetes 
No 13,154 (79.4) 
Yes 3,414 (20.6) 
COPD* 
   No 13,929 (84.1) 
  Yes                                             2,639            (15.9) 
Bowel Incontinence 
   No 13,666 (82.5) 
   Yes                                     2,902 (17.5) 
Urinary Incontinencef 
   No 9,767 (59.0) 
   Yes 6,785 (41.0) 
Urinary tract infection 
    No 15,492 (93.5) 
   Yes                                          1,076 (6.5) 
Falls 
  No 9,693 (58.5) 
  Yes 6,875 (41.5) 
Fractureg 
   No 15,830 (95.5) 
   Yes                                          734 (4.4) 
a-1 missing, b-not spouse/partner, c-2 missing, d-in last 90 days, e-Chronic Obstructive Pulmonary Disease, 
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Table 4.2: Determinants of PIMs and confounding variables with odds ratio (OR) and 95% confidence 
intervals (CI), after multinomial regression (n = 16,568) 
 
 1-2 PIMs > 3 PIMs 
 aOR 95% CI p-value aOR 95% CI p-value 
Age (years) 
65-74 1* 1*  1* 1*  
75-84 0.94 (0.78, 1.14) 0.557 0.69 (0.57, 0.85) <0.001 
85-94 0.76 (0.63, 0.94) 0.009 0.46 (0.37, 0.57) <0.001 
95+ 0.66 (0.48, 0.93) 0.016 0.31 (0.21, 0.44) <0.001 
Sex † 
Female 1* 1*  1* 1*  
Male 1.30 (1.13, 1.49) <0.001 1.36 (1.18, 1.57) <0.001 
Ethnicity 
European 1* 1*  1* 1*  
Māori 0.76 (0.59, 0.98) 0.035 0.50 (0.38, 0.65) <0.001 
Other 0.81 (0.64, 1.05) 0.118 0.63 (0.48, 0.82) 0.001 
Marital status 
Married 1* 1*  1a 1*  
Other 1.04 (0.82, 1.34) 0.716 0.98 (0.76, 1.27) 0.890 
Alcohol 
No 1* 1*  1* 1*  
Yes 1.0 (0.86, 1.16) 0.991 1.04 (0.89, 1.23) 0.597 
Smoking 
No 1* 1*  1* 1*  
Yes 0.95 (0.73, 1.22) 0.686 0.82 (0.62, 1.09) 0.188 
Living arrangements 
Alone 1* 1*  1* 1*  
Spouse only 1.16 (0.88, 1.52) 0.268 1.15 (0.87, 1.53) 0.307 
Other 0.75 (0.59, 0.95) 0.022 0.89 (0.69, 1.16) 0.415 
With child ‡ 0.88 (0.73, 1.07) 0.234 0.83 (0.67, 1.03) 0.099 
Activities of daily living § 
Independent 1* 1*  1* 1*  
Supervision 0.82 (0.68, 0.98) 0.028 0.84 (0.68, 1.00) 0.072 
Limited 0.93 (0.74, 1.17) 0.525 0.88 (0.69, 1.12) 0.311 
Extensive 0.74 (0.56, 0.97) 0.028 0.75 (0.57, 1.01) 0.055 
Maximal 0.67 (0.47, 0.95) 0.023 0.75 (0.52, 1.08) 0.119 
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Dependent+ 0.84 0.58, 1.20) 0.345 0.81 (0.55, 1.17) 0.262 
Self Reported health 
Poor 1* 1*  1* 1*  
Excellent 0.71 (0.48, 1.03) 0.073 0.62 (0.41, 0.93) 0.023 
Good 0.74 (0.56, 0.98) 0.042 0.63 (0.47, 0.85) 0.003 
Fair 0.89 (0.66, 1.19) 0.454 0.78 (0.58, 1.05) 0.105 
Could not  respond 0.85 (0.61, 1.19) 0.363 0.88 (0.62, 1.25) 0.481 
Hospitalisation 
No hospitalisation|| 1* 1*  1* 1*  
Other 1.1 (0.96, 1.28) 0.155 1.19 (1.02, 1.38) 0.021 
No of medications 1.12 (1.11, 1.13) <0.001 1.22 (1.21, 1.23) <0.001 
       
Cancer 
No 1* 1*  1* 1*  
Yes 1.16 (0.95, 1.42) 0.156 1.35 (1.11, 1.66) 0.004 
Dementia 
No 1* 1*  1* 1*  
Yes 1.11 (0.94, 1.31) 0.219 1.26 (1.05, 1.51) 0.011 
Insomnia 
No 1* 1*  1* 1*  
Yes 1.44 (1.23, 1.69) <0.001 1.80 (1.53, 2.11) <0.001 
Depression 
No 1* 1*  1* 1*  
Yes 1.24 (0.96, 1.61) 0.098 1.68 (1.28, 2.19) <0.001 
Anxiety 
No 1* 1*  1* 1*  
Yes 1.12 (0.84, 1.48) 0.431 1.77 (1.32, 2.36) <0.001 
Hemiplegia 
No 1* 1*  1* 1*  
Yes 1.22 (0.79, 1.88) 0.368 0.80 (0.51, 1.27) 0.351 
Parkinson’s Disease 
  No 1* 1*  1* 1*  
  Yes                               0.93 (0.63, 1.37) 0.726 0.86 (0.58, 1.30) 0.487 
Stroke 
   No 1* 1*  1* 1*  
  Yes                                             0.69 (0.58, 0.82) <0.001 0.56 (0.47, 0.67) <0.001 
Coronary heart disease 
  No 1* 1*  1* 1*  
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 Yes 1.07 (0.92, 1.24) 0.402 0.97 (0.83, 1.14) 0.706 
Congestive-cardiac failure                  
  No                                      1* 1*  1* 1*  
 Yes                               0.88 (0.72, 1.07) 0.208 0.76 (0.62, 0.93) 0.008 
Diabetes 
No 1* 1*  1* 1*  
Yes 0.75 (0.63, 0.89) 0.001 0.65 (0.54, 0.77) <0.001 
Chronic Obstructive Pulmonary Disease 
   No 1* 1*  1* 1*  
  Yes                                             0.79 (0.65, 0.96) 0.021 0.51 (0.41, 0.63) <0.001 
Bowel Incontinence 
   No 1* 1*  1* 1*  
   Yes                                     1.11 (0.91, 1.35) 0.300 1.08 (0.88, 1.33) 0.422 
Urinary Incontinence ¶ 
   No 1* 1*  1* 1*  
   Yes 1.07 (0.938, 
1.24) 
0.287 1.13 (0.97, 1.30) 0.110 
Urinary tract infection 
    No 1* 1*  1* 1*  
   Yes                                          0.93 (0.69, 1.26) 0.654 1.19 (0.88, 1.62) 0.248 
Falls 
  No 1* 1*  1* 1*  
  Yes 1.04 (0.91, 1.18) 0.581 1.07 (0.93, 1.24) 0.286 
Fracture †† 
   No 1* 1*  1* 1*  
   Yes                                          1.08 (0.77, 1.51) 0.641 0.96 (0.67, 1.36) 0.838 
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The present study identified the factors associated with prescribing PIMs in the 
older adults of NZ who had undertaken a comprehensive geriatric risk 
assessment. Several important sociodemographic and clinical factors predicted 
the prescription of PIMs in this population. 
4.5.1 Sociodemographic factors of PIMs 
The study demonstrated noteworthy independent relationships between the 
prescription of PIMs and the male gender, the youngest group of older adults (age 
group 65–75 years), NZ Europeans, and the prescription of a greater number of 
medications to each patient, after adjusting for several significant confounders. 
The higher likelihood of prescribing PIMs in the age group of 65–74 years is 
similar to the findings of a study conducted by Willcox et al. in 6171 community-
dwelling older adults.(169) In their study, increasing age was associated with a 
lesser likelihood of being prescribed PIMs. The findings may reflect better 
attention to patient safety concerns and avoidance of PIMs in older adults. Our 
study found an increased prescription of PIMs in NZ Europeans compared to the 
Māori population. This could be attributed to the fact that individuals in the Māori 
group are  less frequently prescribed compared to the non-Māori population.(148) 
To ascertain the findings of our study, it has conclusively been shown that the 
prescription of a higher number of medications increases the risk of prescribing 
PIMs.(170) Patients who were prescribed multiple medications are more likely to 
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have multiple comorbid conditions, treatment by multiple physicians, recent 
hospitalizations; which explain reasons why more PIMs may be prescribed.(170) 
4.5.2 Clinical factors of PIMS 
Our study reported a significant relationship between poor self-health and the 
prescription of PIMs, akin to the observation made by Howard et al. in a clinical 
trial of 889 community dwelling older adults recruited from randomly selected 
family practices in Ontario.(171) A study conducted by Hanlon et al. in frail 
veteran older adults showed that poor self-rated health was a significant 
determinant of prescription of PIMs.(180) 
Individuals hospitalized during the interRAI-HC assessment or in the past 
90 days were prescribed a higher number of PIMs. The results are analogous to 
the findings of a longitudinal cohort Swedish National Study on Aging and Care 
(SNAC) (172) in which individuals over 60 years of age in certain age groups 
were recruited from the Swedish national population and examined. The findings 
are also consistent with a recent study conducted in the community-dwelling 
aging population in NZ, in which the number of prescription medications 
increased considerably after hospital admission in the past 12 months.(181) 
Hospitals are a setting in which older adults are more likely to be exposed to 
PIMs.(182) The impact of hospitalization on PIMs has been investigated in a 
study conducted by Hale et al. (183), and the prescription of PIMs were found to 
be significantly higher after hospital admissions. 
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Our analysis revealed that individuals diagnosed with insomnia, dementia, 
anxiety, depression, and cancer, had an increased likelihood for prescription of 
PIMs. The observations of a cross-sectional study based on annual outpatient 
claims data in older outpatients in Taiwan correlate with a high prevalence of 
prescription of PIMs in patients diagnosed with insomnia.(174) As the age 
progresses, a greater number of adults are diagnosed with insomnia; and, hence, 
physicians prescribe psychoactive medications more frequently to them, thereby 
increasing the prescription of PIMs.(184) Extavour (173) has demonstrated the 
association of a clinical diagnosis of dementia to prescribing of inappropriate 
psychotropic medications, while assessing medications for community-dwelling 
older adults in the USA. A community-based cross-sectional study in Lebanon 
utilizing the 2012 Beers criteria supports the finding of a higher association of 
PIMs with dementia, in patients aged 65 years and over.(22) Findings from the 
SNAC study also point towards a high prevalence of PIMs in the population 
diagnosed with dementia.(172) Sub-optimal prescribing can lead to considerable 
morbidity, especially in older adults with dementia, who may be more vulnerable 
to adverse events.(185) 
Our study reported that individuals with a diagnosis of cancer were prescribed a 
greater number of PIMs than individuals not diagnosed with cancer. Similar 
findings are echoed in a retrospective cross-sectional study conducted in the US, 
analysing PIMs in veterans residing in community living centers, where a strong 
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relationship between cancer and PIMs were reported.(178) PIMs warrant 
substantial interest and concern for prescribing in cancer patients because of the 
perils associated, which include increased risk of falls and/or fractures, cognitive 
impairment, and delirium, all of which can lead to compromised cancer 
management plans (e.g. treatment delays and/or premature treatment 
discontinuation).(186) 
In our study we observed that the prevalence of PIMs was lower in individuals 
who were being supervised and who required maximal or extensive care, 
compared to individuals with functional independence; contrary to the 
observations reported by a study conducted by Miller et al.(167) in community-
dwelling older adults in the US utilizing the 2012 Beers criteria. This study 
examined the determinants of prescription of PIMs by estimating the multivariate 
models of the relationship between PIMs prescription and a broad range of 
socioeconomic and health characteristics in a nationally representative sample of 
US civilian, non-institutionalized population of older adults. The findings of our 
study portray that individuals with a functional dependence had better patient 
safety concerns and avoidance of PIMs with respect to Activities of Daily Living 
(ADL). We also found that individuals diagnosed with COPD, stroke, or CCF 
had a lower prevalence of PIMs prescribed, compared to those not diagnosed with 
these diseases. CCF and COPD were associated with PIMs prescription in other 
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studies conducted globally in hospitalized older adults, especially surgical 
patients.(175-177) 
The factors influencing the prescription of PIMs vary among different studies 
because of different research designs, several versions of the Beers criteria 
utilized and different criteria applied, dissimilar prescribing guidelines in 
different countries, and differing study population characteristics and settings 
(outpatient, continuing care, residential). 
 
4.6 Strength of the study 
A nationwide database was used to identify the associations of prescribing PIMs 
in older adults of NZ. The selection bias is overlooked due to the wide 
prescription coverage in this population. A standardized interRAI HC assessment 
conducted by trained healthcare professionals has the advantage of providing 
valid clinical, social, and functional information. Several determinants included 
in the multivariate regression model, such as self-reported health, living status, 
and cognition, are rarely available in studies that used the administrative claims 
data; hence, this study provides a unique perspective to the factors associated with 
the prescription of PIMs in the geriatric population. The long-term implications 
of this study have the potential to impact prescribing in the older population of 
NZ, and help in developing an appropriate tool for prescribing. 
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Some of the medications listed in the Beers criteria were not available in NZ or 
not funded by PHARMAC (Appendix 2.2). Potential bias such as the use of the 
cross sectional study design presents as an inherent limitation and can limit the 
applicability of the findings. The findings of the study may not be generalized to 
other countries because of different healthcare systems, prescribing guidelines, 
and treatment expenditures, as they influence prescribing patterns. The 
population studied is a high-risk population requiring complex care needs, 
different from other study populations. Medications such as over-the-counter 
medications not captured by the prescription claims dataset may have under-
estimated the exposure to PIMs in this study population. We could not assess the 
dispensing of anti-psychotics for behavioural problems of dementia or for short-
term use as an anti-emetic, and thus we excluded them from the analysis. The 
Beers criteria 2015 does not consider the prescription of anti-psychotics for 
schizophrenia and bipolar disorders as PIMs, and, hence, anti-psychotic 
prescriptions for these conditions were excluded from the analysis. The interRAI-
HC assessment does not capture the diagnoses of atrial fibrillation, 
hypogonadism, recently decompensated heart failure, removal of the pituitary 
gland, delirium, Barrett’s esophagitis, gastroparesis, pathological hypersecretory 
condition, peptic ulcers, lower urinary tract symptoms, chronic kidney disease, 
benign prostatic hypertrophy, and, hence, these diagnoses were excluded from 
the analysis. Hypertension is not diagnosed by the interRAI-HC assessment; 
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hence, the prescription for clonidine and peripheral alpha-blockers as anti-
hypertensive agents could not be confirmed. The information to identify specific 
conditions for prescriptions with estrogens was unavailable. 
 
4.8 Conclusion 
The present study found several sociodemographic and clinically relevant factors 
associated with the prescription of PIMs. Together with the results of our study, 
the published evidence demonstrates that the prescription of PIMs to older adults 
is influenced by a variety of factors. We highlight a greater number of 
medications and recent hospitalizations as a factor directly related to the 
prescription of PIMs. Other important factors include functional status, reported 
self-health, and the diagnosis of dementia. Identification of the modifiable 
determinants of PIMs, such as number of medications, is emphasized during the 
first completed comprehensive geriatric assessment. Targeted strategies to reduce 
modifiable determinants of PIMs in subsequent assessments has the potential to 
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Parts of this chapter are based on the following peer-reviewed publication: 
Bala SS, Jamieson HA, Nishtala PS. Determinants of prescribing potentially 
inappropriate medications in a nationwide cohort of community dwellers with 
dementia receiving a comprehensive geriatric assessment. International Journal 
of Geriatric Psychiatry. 2019:34:153– 61. 
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5.1 Context 
The worldwide incidence of dementia is expected to increase to 81 million by the 
year 2040, primarily because of the progressive nature of the disorder, which 
involves worsening of neurocognitive impairment and loss of basic functions in 
daily life.(39, 187, 188) In 2016, the estimated prevalence of dementia in New 
Zealand (NZ) was more than 62,000, which is predicted to increase to 170,000 in 
2050.(40) One in every four international Resident Assessment Instrument‐Home 
Care (interRAI‐HC) evaluated individuals in 2016 to 2017 in NZ were diagnosed 
with dementia, of which 35% needed extensive assistance or were completely 
dependent, and 30% showed daily episodes of disturbing behaviours, such as  
‘exit seeking’ or being aggressive.(30) The interRAI‐HC tool gathers information 
on physical, mental, social, and cognitive domains of the health of 
residents/clients living in home care settings.(189) 
A study utilizing the Beers criteria, conducted in rural community‐dwelling older 
adults in the United States, identified half of the population of older adults 
utilizing over‐the‐counter and prescribed inappropriate medications.(190) 
Prescribing medications for older adults with dementia is challenging because of 
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the risks associated with cognitive decline, behavioural and psychological 
disturbances, prescription of multiple medications, and their associated costs.(43, 
44) Long‐term utilization of medications in older individuals with impaired 
physical and cognitive function has been associated with increased risks of 
hospitalization and mortality.(191)  
The 2015 Beers Criteria is often used as a tool for assessing the appropriateness 
of prescribing medications in the geriatric population.(162) A systematic review 
among older adults with cognitive impairment and dementia reported a varied 
prevalence of prescription of PIMs of 10.2% to 56.4% across Europe, Australia, 
and the United States; and the Beers criteria were applied for assessing PIMs in 
majority of the studies.(9) Another recent literature review reported that among 
the five studies conducted in ambulatory home‐dwelling patients diagnosed with 
dementia that used the Beers criteria, the prevalence of prescription of PIMs 
ranged from 16.2% to 33%, and PIMs were found to be associated with gender, 
ethnicity, number of medications prescribed, and varied medical conditions.(10)  
An understanding about the prevalence and determinants of PIMs can help 
prevent adverse effects and improve the quality of prescribing in this vulnerable 
age group. To our knowledge, this is the first study conducted to evaluate the 
predictors of prescribing PIMs in older adults with dementia, receiving 
comprehensive geriatric risk assessments. These assessments capture a suite of 
sociodemographic and clinical variables, which have not been previously 
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investigated. The study aimed to identify the prevalence and associations of 
prescribing PIMs in a nationwide cohort of community dwellers with dementia. 
The overarching objective of the study was to identify the factors associated with 
inappropriate prescribing in older adults diagnosed with dementia, identified by 
the 2015 version of the Beers criteria, utilizing the 2015 interRAI-HC dataset. 
 
5.2 Methodology 
The Human Ethics Committee, University of Otago, NZ approved the 
proceedings of the study (ethical approval number 15/CEN/45/AM02). 
5.2.1 Data source 
The cross‐matched 2015 interRAI-HC and PHARMS (Pharmaceutical Claims 
Data Mart) dataset was utilized for the present study. 
5.2.2 Study population 
The eligible study population comprised community dwellers (≥65 years of age) 
in NZ who had undergone the first interRAI-HC comprehensive geriatric risk 
assessment in 2015.Our study had a retrospective design, tracking the prevalence 
of PIMs and dementia, and delineating factors associated with prescription of 
PIMs in older adults with dementia. The personal information of the individuals 
was de-identified in the dataset. 
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5.2.3 Exposure to potentially inappropriate medications 
PIMs were defined according to the list of medications mentioned in the 2015 
Beers criteria (21), to be avoided in individuals diagnosed with dementia, which 
comprised the prescription of psychotropics, including antipsychotics, 
medications with anticholinergic properties (MAP), benzodiazepines, 
nonbenzodiazepines, benzodiazepine receptor agonist hypnotics, and H2 receptor 
antagonists (Table 5.1). We have excluded medications listed in the 2015 Beers 
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Table 5.1 List of medications to be avoided in individuals diagnosed with dementia 
 









Chlorpheniramine Homatropineb Haloperidol Cimetidine Alprazolam 
Propantheline Chlorpromazine Trifluoperazine Ranitidine 
 
Lorazepam 
Orphenadrine Clozapine Fluphenazine Famotidine Oxazepam 
Diphenhydraminea Olanzapine Chlorpromazine  Temazepam 
Benztropine Thioridazine Thioridazine  Triazolam 
Amitriptyline Trifluoperazine Aripiprazole  Clonazepam 
Clomipramine Oxybutynin Quetiapine  Diazepam 
Doxepin (>6 mg) Solifenacin Ziprasidone  Flurazepam 
Imipramine Tolterodine Risperidone  Meprobamate 
Nortriptyline Disopyramide Clozapine   
Paroxetine Prochlorperazine Olanzapine   
Trimipramine Atropine    
Promethazine     
a=oral, b=excludes ophthalmic 
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5.2.4 Diagnosis of dementia 
Dementia was diagnosed by the Minimum Data Set (MDS) Cognitive 
Performance Scale (CPS).(42)  
5.2.5 Covariates 
The individuals were grouped according to the age groups: 65–74 years, 75–84 
years, 85–94 years, and 95 years and above. Based on the literature review of 
known predictors of inappropriate prescribing in older adults with and without 
dementia, explanatory variables that were tested for their influence on prescribing 
patterns were as follows: 
1. Sociodemographic (12, 14, 22, 161, 167, 181): Age, gender, ethnicities, marital 
status, living arrangements, alcohol intake, and smoking history. 
2. Clinical (167, 181, 192-194): Activities of daily living, self‐reported health, 
hospitalization, and number of medications. 
5.2.6 Statistical analysis 
The potential impact of different explanatory variables on the outcome variable 
(PIMs) was analysed using logistic regression models. Individuals with a 
diagnosis of dementia were flagged as a binary variable; those with the diseased 
condition were coded as 1, and the coding for no dementia was 0. Descriptive 
analysis was conducted utilizing the IBM SPSS version 24.(141) Logistic 
regression analysis was performed using StataCorp Release 14.2.(179) We 
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utilized the “STrengthing the Reporting of Observational studies in 




The current analysis is based on data collected from 16,568 interRAI-HC 
assessments from 1st January 2015 to 31st December 2015, who received at least 
one prescription medication funded by PHARMAC (the Pharmaceutical 
Management Agency). Our observations suggest that the female population 
comprised 60.1% (9,964). The mean (SD) age of the population was 82.35 (7.6) 
years. Individuals of all ethnicities were included in the study. NZ Europeans and 
Māori were studied particularly, as they represent the largest ethnicities in 
NZ.(14) 13.2% (2,190) individuals of the study population were diagnosed with 
dementia. Dementia was marginally more prevalent in males (14.6%), compared 
to females (p = 0.001), and higher in the Māori ethnicity group of individuals 
(16.6%). The sociodemographic characteristics of the study population and 
factors associated with prescribing of PIMs, after adjustment for confounders in 
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Table 5.2: Predictors of PIMs and confounding variables with odds ratio (OR) and 95% confidence 
intervals (CI), after logistic regression (n= 16,568) 






aOR 95% CI p-value 
Age (years)      
65-74 3,048 (18.4) 1† 1  
75-84 6,776 (40.9) 0.84 (0.69, 1.01) 0.058 
85-94 6,192 (37.4) 0.64 (0.53, 0.77) 0.000 
95+ 552 (3.3) 0.53 (0.38, 0.73) 0.000 
Sex ‡      
Female 9,964 (60.1) 1† 1†  
Male 6,603 (39.9) 1.24 (1.09, 1.41) 0.001 
Ethnicity      
European 14,639 (88.4) 1† 1†  
Māori 957 (5.8) 0.59 (0.47, 0.76) 0.000 
Other 972 (5.9) 0.68 (0.54, 0.87) 0.002 
Marital status      
Married 6,607 (39.9) 1† 1†  
Other 9,961 (60.1) 1.01 (0.80, 1.28) 0.916 
Alcohol      
No 13,225 (79.8) 1† 1†  
Yes 3,343 (20.2) 1.02 (0.88, 1.19) 0.760 
Smoking      
No 15,653 (94.5) 1† 1†  
Yes 915 (5.5) 0.85 (0.66, 1.09) 0.209 
Living arrangements     
Alone 8,019 (48.4) 1† 1†  
Spouse only 5,447 (32.9) 1.14 (0.88, 1.50) 0.327 
Other 1,292 (7.8) 0.79 (0.63, 0.99) 0.050 
With child §  1,810 (10.9) 0.86 (0.71, 1.03) 0.119 
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Activities of daily living ¶ 
Independent 9,985 (60.3) 1† 1†  
Supervision 2,143 (12.9) 0.83 (0.69, 0.99) 0.035 
Limited 1,782 (10.8) 0.94 (0.76, 1.18) 0.642 
Extensive 1,046 (6.3) 0.77 (0.60, 1.00) 0.053 
Maximal 730 (4.4) 0.74 (0.53, 1.02) 0.066 
Dependent+ 880 (5.3) 0.84 (0.60, 1.16) 0.288 
Self-reported health     
Poor 1925 (11.6) 1† 1†  
Excellent 522 (3.2) 0.62 (0.43, 0.89) 0.010 
Good 6,806 (41.1) 0.65 (0.49, 0.85) 0.002 
Fair 5,695 (34.4) 0.80 (0.60, 1.06) 0.124 
Couldn’t  respond 1,620 (9.8) 0.82 (0.59, 1.13) 0.229 
Hospitalisation      
No hospitalisation  
(in last 90 days)  
8,602 (51.9) 1† 1†  
Other 7,966 (48.1) 1.11 (0.97, 1.27) 0.129 
Dementia      
No 14,378 (86.8) 1† 1†  
Yes 2,190 (13.2) 1.17 (0.99, 1.37) 0.057 
No of meds                                          1.15 (1.14, 1.16) 0.000 
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Overall, we observed that 66.9% (1,465/2,190) of older adults diagnosed with 
dementia were prescribed PIMs. 59.6% of PIMs (873/1,465) constituted 
potentially inappropriate MAP. Overall, 39.9% (873/2,190) of the individuals 
diagnosed with dementia were prescribed MAP Figure 5.1). 
 
Figure 5.3: The study population 
Total population=16568 
Individuals diagnosed with dementia=13.2% 
Individuals with dementia who were prescribed PIMs=66.9% 
Individuals diagnosed with dementia and prescribed PIMs with anticholinergic properties=39.9% 
PIMs= potentially inappropriate medications 
 
5.3.1 Sociodemographic predictors 
Individuals more than 85 years of age were less likely to be prescribed PIMs, 
compared to individuals aged 65 to 74 years (aOR = 0.64, CI, 0.53‐0.77, for 
individuals aged 85–94 years, and aOR = 0.53, CI, 0.38‐0.73, for individuals over 
95 years). Males were more likely to be prescribed PIMs (aOR = 1.24, CI, 1.09‐
1.41) compared to females. The Māori ethnic group (aOR = 0.59, CI, 0.47‐0.76) 
and the other ethnic groups (aOR = 0.68, CI, 0.54‐0.87) were less likely to be 
prescribed PIMs, compared to the NZ Europeans. 
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5.3.2 Clinical factors associated with PIMs 
Older adults who were prescribed a greater number of medications were more 
likely to be prescribed PIMs (aOR = 1.15, CI, 1.14‐1.16), compared to those 
prescribed a single medication. With respect to the activities of daily living, older 
adults who were being supervised (aOR = 0.83, CI, 0.69‐0.99) were less likely to 
be prescribed PIMs, compared to individuals who were independent in their self‐
performance and capacity. Older adults who reported excellent (aOR = 0.62, CI, 
0.43‐0.89) and good self‐health (aOR = 0.65, CI, 0.49‐0.85) had a lesser 




We reported the prevalence of prescription of PIMS and identified the 
sociodemographic and clinical variables associated with the prescription of PIMs 
among community‐dwelling older adults diagnosed with dementia. Several 
studies investigating PIMs in older adults have been conducted in NZ that utilized 
the Beers criteria, and have focused on prescribing in community‐dwelling or 
hospitalized older adults.(12, 14, 166)  
This work extends the collaboration with Nishtala and Narayan in analysing the 
medication data from the interRAI Home Care in New Zealand with a new focus 
on older adults with dementia by applying the 2015 Beers criteria in order to 
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examine the associations of inappropriate prescribing exclusively in community‐
dwelling older adults with dementia in NZ, who have received a comprehensive 
geriatric risk assessment. 
The NZ interRAI annual report (30) in 2016 to 2017 noted a 1.2 times higher 
prevalence of dementia in males, compared with females, findings consistent with 
those in our study. Similarly, in the present study, male individuals diagnosed 
with dementia were more prone to be prescribed PIMs, compared with females; 
which is similar to the findings of a recent study in Finland (62) that reported the 
male gender as a risk factor for initiation of PIMs in community‐dwelling older 
adults with Alzheimer's disease; and the research conducted in Korea, which 
analysed the trends in prescribing atypical antipsychotics in geriatric patients with 
dementia.(195) Numerous other studies have reported a higher rate of 
inappropriate medication use in older women than in men of the same age‐group, 
although the clinical relevance of this association remains uncertain.(196-198) 
Our study observed a high prevalence of dementia in the Māori group, 
comparable with that observed in a study conducted in NZ to assess an indigenous 
approach for the diagnosis and management of dementia (199), and similar to the 
findings of the NZ interRAI annual report (30) of 2016-2017. It has been observed 
that the Māori population over the age of 50 years have had worse health 
outcomes and a greater burden of chronic ailments than non-Māori individuals of 
the same age-group.(200) The prevalence of PIMs (68.4%) in NZ Europeans with 
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dementia exceeded the occurrence in all other ethnic groups of individuals, 
identical to the findings of other studies calculating the prevalence of PIMs in 
older adults in NZ.(14, 166) This could be attributed to NZ Europeans being the 
predominant ethnic group in New Zealand, comprising 70.2 % of the country's 
inhabitants.(201) A higher proportion (72.3%) of the relatively younger group 
(65‐75 years of age) of older adults with dementia were prescribed PIMs, which 
reflects the findings of the study performed by Hyttinen et al to evaluate PIMs 
prevalence in community‐dwelling older adults with and without the diagnosis of 
Alzheimer's disease.(62) These findings could potentially be attributed to an 
increased awareness concerning the prescription of PIMs in individuals of the 
older age group.(202) 
There was a high prevalence of prescription of PIMs (66.9%) in older adults 
diagnosed with dementia in our study, comparable to the prevalence (62%) in a 
study conducted in community‐dwelling older adults in the United States.(145) 
This is a significant finding of our study. Researchers in Australia have also 
reported a prescription of at least one PIM as 56.4% among individuals with 
dementia living in residential aged care facilities.(203) A study of six residential 
care homes in England (198) observed the prevalence of at least one PIM 
prescribed in 46.2% and 40.9% of the older adults diagnosed with dementia, 
utilizing the Screening Tool of Older People's Prescription (STOPP) criteria, 
reviewed at two time‐points, 16 weeks apart. A direct international comparison 
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of the prevalence of PIM prescriptions with our findings is challenging because 
of the differences between the PIMs lists used, and the varied population studies.  
Holmes et al have developed a tool for the assessment of appropriate medication 
prescribing in advanced dementia, in which the primary goal is palliation of 
symptoms.(204) There is a similar need to arrive at a global consensus through 
research on appropriate prescribing in older adults, presenting with different 
stages of dementia. One of the most significant findings of our research suggest 
that 59.6% of the PIMs prescribed belonged to the class of MAP; and 39.9% of 
the population studied were prescribed MAP that were termed inappropriate to 
prescribe in older individuals diagnosed with dementia, according to the 2015 
Beers criteria.. A study by Somers et al (205) reported a high anticholinergic 
burden of PIMs in residential aged care facilities in Melbourne. A study by Cross 
et al (206) in Australia also reported a clinically significant anticholinergic burden 
in older adults attending Memory Clinics. MAP are specifically associated with 
negative outcomes in older adults diagnosed with dementia, such as risk of falls, 
delirium, worsening of cognitive function, and increased mortality.(207, 208) 
MAP are notorious for peripheral side effects, which include dry mouth, 
constipation, urinary retention, and bowel obstruction; and the central side effects 
such as impaired concentration, confusion, attention deficit, and impairment of 
memory.(207) PIMs with anticholinergic properties may also inhibit the potential 
benefits of cholinesterase inhibitors, which is the main pharmacological class, 
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currently approved for the management of dementia.(209) Several researchers 
have attested that MAP may be associated with an increased risk for the 
development of sustained cognitive deficits, which can range from mild cognitive 
impairment to dementia.(47)  
The results of the logistic regression analysis conducted in our study showed that 
the likelihood of PIMs increased with the number of medications prescribed, 
which is akin to the findings of the research performed in older adults with 
dementia in care homes in the United Kingdom.(198) A study performed in the 
United Kingdom, utilizing the primary care database of anonymised electronic 
health records from general practice, witnessed that patients over 65 years of age 
diagnosed with dementia, and taking multiple medications, were more likely to 
be prescribed antipsychotics.(210) A higher number of medications being 
prescribed may indicate the presence of multiple comorbidities. Medication 
interactions and non-adherence are other risk factors that may have adverse 
consequences among older adults with dementia, which are linked to the 
prescription of a high number of prescribed medications.(208) 
In our study, individuals who reported poor self‐health had an increased 
likelihood of being prescribed PIMs, identical to the results of a study conducted 
in the United States to assess potentially inappropriate anticholinergic medication 
prescription in home‐dwelling older adults with dementia.(202) The Bronx Aging 
Study (211) revealed that patients with poor or fair ratings of self‐perceived 
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health utilized more prescription medications. Scores on self‐perceived health 
status may be an appropriate measure of the syndrome. This is supported by the 
conclusion that subjects reporting fair and poor ratings on self‐perceived health 
have increased numbers of physician visits.(211) 
Contrary to the analysis of studies conducted in individuals diagnosed with 
dementia in Sweden (172) and in eight European countries (18), a striking result 
to emerge from our data is that the PIMs prevalence was higher in individuals 
who were functionally independent with respect to the Activities of Daily Living 
(ADL). 
Our study found an increased prescription of MAP in older adults diagnosed with 
dementia. Several studies have shown that prescription of MAP can adversely 
impact cognition, physical function, and can also increase the risk of mortality.  
 
5.5 Future research 
We aimed to utilize the interRAI assessments for finding alternatives to the 
currently prescribed MAP in older adults with dementia, thereby reducing the 
prescribing of PIMs in this vulnerable population. 
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5.6 Strength of the study 
The strength of this study includes the use of a national comprehensive geriatric 
assessment, the interRAI-HC, to record social attributes, clinical diagnosis and 
medication use information in a substantial number of subjects, and the inclusion 
of older adults with dementia. Selection bias is mitigated by the wide prescription 
coverage in this population. Standardized interRAI‐HC assessments conducted 
by trained healthcare personnel facilitates the provision of valid clinical, social, 
and functional data for research purposes. Various predictors incorporated in the 
multivariate regression model, such as living arrangements, activities of daily 
living, and self‐reported health are seldom seen in studies using administrative 
claims data; hence, this study provides a unique perspective to the determinants 
of prescription of PIMs in older adults with dementia. An additional strength is 
the application of the updated 2015 Beers criteria. 
 
5.7 Limitations 
While considering the prevalence and associations of PIMs, the individual 
psychotropic medications were not studied. It was not possible to delineate the 
subtypes of dementia. The retrospective analysis may not have been as competent 
as a prospective research in outlining the findings of the study. Potential bias such 
as the use of the cross sectional study design presents as an inherent limitation 
and can limit the applicability of the findings. The geriatric risk assessments are 
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conducted in older adults living in the community specifically requiring complex 
care needs, which is different from surveyed populations of older adults living in 
the community. Hence, the findings of this study might not be applicable to 
community‐dwelling older adults in various countries because of variances in the 
population, health systems, prescribing guidelines, and the cost of medications, 
as all these factors influence prescribing patterns; however, country‐specific 
guidelines can be developed using this information. The study design is cross‐
sectional, hence, only the associations of prescribing PIMs have been highlighted 
and the causality cannot be established. 
5.8 Conclusion 
In the present study, we observed that majority of the individuals diagnosed with 
dementia were prescribed PIMs, indicating that the quality of prescribing needs 
to be improved. Furthermore, important socio-demographic predictors like the 
male gender, the European ethnicity, relatively younger aged individuals; and 
clinical predictors like the prescription of MAP, a higher number of medications 
prescribed, poor self‐health, functionally independent individuals, were identified 
as risk factors for prescribing PIMs in older adults diagnosed with dementia. 
Reviewing the modifiable predictors of prescribing PIMs could significantly 
reduce the prevalence of inappropriate prescribing in this vulnerable population. 
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Dementia is a chronic and progressive syndrome characterised by the 
deterioration of cognitive function, thinking, behaviour, and loss of the 
ability to perform routine activities.(36) The global incidence of dementia is 
9.9 million per year.(38) Due to a lack of effective clinical management for 
age-related neurodegenerative disorders, research has primarily focussed on 
the detection of potential modifiable risk-factors, especially medication 
induced cognitive impairment, with a view to delay cognitive decline and 
prolong self-sufficiency in this vulnerable population.(45) 
Medications with anticholinergic properties (MAP) are widely prescribed for 
a variety of conditions, of which the most common indications are overactive 
bladder, depression, seasonal allergies and epilepsy.(46-48) Antispasmodics, 
antiparkinsonians, and antimuscarinics achieve the intended therapeutic 
outcome with a few side effects, whereas most others including the first-
generation antihistamines, tricyclic antidepressants, certain antipsychotics, 
etc., have unintended anticholinergic effects that are not the principal 
therapeutic activity.(47) It is common to empirically prescribe older adults 
with medications not routinely recognised as having anticholinergic 
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properties but based on their anticipated therapeutic benefits neglecting the 
risk of cumulative anticholinergic burden (ACB).(212) MAP block the 
neurotransmitter acetylcholine to bind with the cholinergic receptors in the 
central and peripheral nervous systems.(46, 47, 53) They may accelerate 
neurodegeneration by impeding the immune regulatory process of 
cholinergic nicotinic receptors which inhibit the inflammatory reactions in 
the nervous system.(49) Individuals with dementia exhibit a greater risk of 
developing medication induced increased cognitive impairment.(50) They 
are more sensitive to the anticholinergic effects in the central nervous system 
because of age related changes in pharmacokinetics and pharmacodynamics, 
which include, but are not restricted to a reduction in acetylcholine mediated 
transmission in the brain and increased permeability of the blood-brain 
barrier. This in turn could lead to worsening of cognitive function affecting 
the working memory, attention, psychomotor speed; sustained cognitive 
defects which include mild cognitive impairment or dementia; neurological 
adverse effects such as impaired concentration, confusion, attention deficit, 
and delirium; peripheral side effects which include dry mouth, constipation, 
urinary retention, blurred vision, and bowel obstruction.(47, 213) (54, 56, 
214, 215) A study conducted in Norway demonstrated that higher 
anticholinergic drug scale scores were associated with peripheral and not 
cognitive markers of cholinergic blockade, which corroborates that 
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medications with both peripheral and central anticholinergic properties are 
not recommended in older adults with dementia.(216) MAP are also known 
to attenuate the therapeutic benefits of cholinesterase inhibitors which 
comprise donepezil, rivastigmine, and galantamine, the only class of 
medications currently approved for the pharmacological management of 
dementia.(50, 54, 56, 217)  
Many studies conducted globally have linked prolonged exposure to MAP 
with long-term cognitive decline (45, 47-49, 51-53, 218-220), and the Beers 
and Screening Tool of Older Persons’ potentially inappropriate Prescriptions 
(STOPP) criteria have termed MAP as potentially inappropriate in older 
adults with dementia.(48) In the previous chapter, utilizing the New Zealand 
(NZ) International Resident Assessment Instrument-Home-Care (interRAI-
HC) dataset, we observed that the prevalence of dementia in NZ was 13%, 
of which 67% were prescribed potentially inappropriate medications (PIMs) 
applying the Beers 2015 criteria, and the MAP constituted 60%.(215) 
Clinical research has suggested prescription of alternatives to these 
potentially unsafe medications as the way forward in older adults with 
dementia.(53-55, 221) The cumulative effect of prescription of MAP to each 
individual is referred to as the ACB.(56, 57)  
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The Beers and the STOPP/START criteria are the most commonly used 
validated criteria for identifying inappropriate prescribing globally. The 
Beers criteria mentions a few medications with strong anticholinergic 
properties to be avoided in older adults with dementia (12); however, the list 
is not comprehensive and there is no mention of alternatives for the same. 
The STOPP criteria mentions that anticholinergics should be discontinued in 
individuals with dementia; however, there are no medications listed, and no 
alternatives provided.(23) The alternatives for high-risk medications in 
older-adults developed by Hanlon et al (222) is a comprehensive tool 
encompassing most disorders, however, not all MAP have been detailed with 
specific reference to prescribing in older adults with dementia. Similarly, the 
practical guide to assess anticholinergic burden by Boustani et al (54) was 
formulated in 2008; many MAP have been identified thereafter; and all the 
medications in this guide have been listed without considering the 
indications and therapeutic classification of medications. A number of 
clinical scales (212) have been designed to detect and assess the MAP 
exposure at a given point in time, and there is no ideal measure as the number 
of medications listed and the rating of the anticholinergic activity for each 
medication varies considerably.(56, 58) As per our knowledge, although 
there have been many scales for classifying medications with high and 
moderate anticholinergic activities, there is no tool in the existing literature 
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which gives a comprehensive list of the therapeutic alternatives to MAP 
prescribed for comorbidities in individuals with dementia. 
 
6.2 Methodology 
Based on the current literature review of the ACB scales and serum 
anticholinergic activity of various medications, we collated known 
information of the level of anticholinergic activity for each medication, and 
developed recommendations for prescribers, focussing on pharmacological 
alternatives for the currently prescribed MAP for older adults with dementia 
presenting with co-morbidities (Appendix 6.1) A few significant classes of 
medications have been excerpted in Table 6.2. We searched the Medline and 
Embase database for observational and experimental studies that measured 
the anticholinergic activity of medications. The search terms used were 
‘anticholinergic burden’, ‘anticholinergic drugs’, ‘dementia’, ‘potentially 
inappropriate medications’, ‘older adults’. 457 articles were downloaded 
from computerised databases, 84 were manually searched, 130 duplicate 
records were removed, 411 articles were screened in total, and 354 of the full 
text articles were assessed for eligibility.  After excluding the articles based 
on the inclusion-exclusion criteria, 46 were included in the literature review. 
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All the medications were enumerated chronologically according to the New 
Zealand Formulary (NZF).(223) Medications were classified according to 
the Anatomical Therapeutic Chemical-Defined Daily Dose (ATC-DDD) 
Methodology. (224) Medications were sorted according to the those with 
high/moderate anticholinergic activity and their low/no anticholinergic 
activity substitutes. To achieve an adequately comprehensive range of 
medications, all the existing scales measuring the anticholinergic activity of 
various medications were utilized. When we observed a discrepancy in the 
measure of the anticholinergic activity of a particular medication by different 
scales, precedence was given to the study that reported a higher 
anticholinergic activity. 
Medications with no anticholinergic activity were assigned the score ‘0’, 
those with moderate anticholinergic activity were allocated the score ‘1’, and 
medications with high anticholinergic activity were given the score ‘2’; with 
a positive correlation to the highest score with maximum impact. The current 
intervention was an attempt to identify medications with high or moderate 
anticholinergic activity (HOMAA) and substitute a low or no anticholinergic 
activity (LONAA) alternative for them wherever possible, according to the 
therapeutic classification of medications. For example, if an individual with 
dementia was prescribed Furosemide [anticholinergic activity (AA=2)], we 
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substituted it with the other high-ceiling diuretic Sulfonamide- Bumetanide 
(AA=0); similarly, Alprazolam (AA=2) could be replaced either by 
Diazepam, Oxazepam, or Lorazepam (AA=0) as an anxiolytic. For a few 
classes of medications including H2 Receptor Antagonists, Proton pump 
Inhibitors, all the medications possessed either high or moderate 
anticholinergic activity, and hence no alternatives were suggested. In such 
cases, the prescribers’ discretion should be employed to recommend 
medications belonging to a different therapeutic class and having almost the 
same medication action. We computed the ACB score for each patient by the 
aggregate of the numbers assigned for each medication’s anticholinergic 
activity.  
Our study takes a theoretical approach, whereby individuals with dementia 
were considered for the probability of a reduction in their overall ACB by 
altering their current medication regime based on relevant practice 
guidelines. The tool was incorporated into the New Zealand International 
Resident Assessment Instrument (interRAI-HC) dataset to test the 
amendment in ACB. The two groups of results (the initial total ACB and the 
total ACB after possible reductions) were subjected to a Paired Samples T 
test using SPSS to ascertain if the two groups were significantly different to 
demonstrate a meaningful outcome. Medications whose anticholinergic 
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activity could not be determined by the literature review were re-checked in 
Goodman and Gilman’s The Pharmacological basis of Therapeutics, 13th 
edition.(225) 
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Table 6.1: Pharmacological alternatives for the currently prescribed MAP for older 
adults with dementia presenting with co-morbidities 
 









Low or no 
anticholinergic 
activity alternatives 
1. Anxiolytics (212, 226-231) 
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*-Anticholinergic activity not known, (M)-Moderate anticholinergic activity, Medications in italics-
could have high/moderate/low anticholinergic activities based on the evidence provided by different 
studies 
 





iv. B Blockers 
 























































3. Anti-secretory medications 
and mucosal protectants                  
Anti-Hpylori and NSAID 
associated ulcers 
medications(228, 229, 231, 235-237) 
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The interRAI-HC dataset constituted 75,410 community dwelling older adults 
aged 65 and above, of which 12,983 (17.2%) were diagnosed with dementia. 
Dementia was diagnosed through clinical assessments in the interRAI-HC 
dataset. 49.5% (6,430) of these individuals were prescribed at least one MAP. 
The Anticholinergic burden (ACB) is the cumulative effect of prescription of 
MAP to each individual. We computed the ACB score for each patient by the 
aggregate of the numbers assigned for each medication’s anticholinergic activity. 
The two groups of results: the initial total ACB and the total ACB after possible 
reductions were subjected to a Paired Samples T-test using SPSS version 26 to 
ascertain if the two groups were significantly different. We compared the results 
of the ACB before and after the theoretical intervention of the pharmacological 
alternatives to MAP.  The mean ACB score before the intervention was calculated 
as 2.24, and after intervention as 1.75.  By incorporation of the recommendations, 
we observed a mean reduction of the ACB by 0.49 (95% CI, 0.47-0.51). We could 
reduce the prescription of anticholinergic medications by suggesting therapeutic 
alternatives in 6,430 older adults with dementia (31.2%), with an absolute 
reduction in 8.2% individuals. 
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 Based on the current data of a high prevalence of prescription of MAP in older 
adults with dementia globally, we developed recommendations for prescribing 
their alternatives, and incorporated them in the interRAI-HC dataset. The results 
of our study indicate that there was a significant theoretical reduction in the ACB 
in these individuals when our recommendations for the therapeutic alternatives to 
MAP was utilized. The authors envision this study as an initial step to more robust 
clinical intervention studies. At present, prescribers are suggested to take into 
consideration the recommendations as a decision support tool, along with 
rationalizing prescribing in individuals with dementia to enhance safe 
pharmacotherapy. We also suggest health professionals to implement these 
recommendations for prescribing all older adults (>65 years of age) to prevent 
the onset of cognitive impairment and dementia. More studies are required to 
validate the tool in actual clinical settings. The integration of the pharmacological 
alternatives to the currently prescribed MAP in the hospital information systems 
(HIS) may have the potential to improve therapeutic outcomes in this vulnerable 
population.  
Dementia prevention is a public health priority.(77) Although the currently 
approved medications for the management of dementia facilitates the 
improvement of cognition, memory, communication, performance of routine 
activities, they do not inhibit the disease progression in the CNS.(78, 79) 
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Research has ascertained that the incidence of dementia and of most non-
communicable disorders can be reduced by multi-domain lifestyle modifications 
such as exercising regularly, avoiding smoking and alcohol intake, weight 
management, incorporating a healthy diet, maintaining normal levels of blood 
pressure, cholesterol, and sugar.(80, 81) It is also advisable to keep a check on 
the dementia aggravating factors including depression, social isolation, cognitive 
inactivity. Several types of cognitive therapy are now available, which could 
benefit individuals likely to develop dementia. Various psychosocial and 
educational interventions have been shown to improve the quality of life and 
quality of care of community dwelling older adults with dementia.(238, 239) An 
awareness must be created among health professionals by educating them about 
the potential risks associated with the prescription of MAP, and to minimize their 
use over time. Together, the prescriber and the patient or the care-taker could 
discuss and review the benefits and drawbacks of both the prescribed and over-
the-counter medications the patient is being administered, and make an informed 
decision to switch to alternative medications with less anticholinergic cognitive 
effects.(54) Furthermore, a gradual withdrawal of specific agents is suggested to 
avoid rebound anticholinergic or psychiatric effects.(54) Deprescribing trials in 
individuals with dementia can evaluate the potential risks associated with 
prescribing MAP and can help restore cholinergic neurotransmission in the CNS 
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that improve cognitive performance and ultimately reduce the risk of developing 
or delay the onset of dementia.(55)  
6.5 Strength  
This is the first study that delineates a comprehensive list of medications listed in 
the NZF, sorts the medications with HOMAA or LONAA, and suggests 
alternatives according to the therapeutic classification of medications. The 
legendary Beers, STOPP criteria, the alternatives to high-risk medications by 
Hanlon et al, the practical guide for anticholinergic use by Boustani et al, and the 
other guidelines have not provided a complete list of alternatives to MAP in older 
adults with dementia. The strength of our outlined alternatives is that they are 
based on the information contained in guidelines, meta-analyses, randomized 
controlled trials, and rigorous observational studies. The standardized interRAI-
HC dataset, a comprehensive geriatric assessment, conducted by trained 
healthcare professionals has been valuable in providing valid clinical 
information. The incorporation of the alternatives to MAP in interRAI-HC has 
been successful in theoretically reducing the ACB, which enhances the 
significance of the study.  
 
6.6 Limitations 
The categorization of medications was solely based on the anticholinergic 
properties of medications, irrespective of their ‘safety profile’; assuming that the 
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NZF was prepared after evaluating the adverse medication reactions, indications, 
interactions for each medication per se. The applicability of the tool in different 
countries cannot be ascertained as the medications listed in the tool have been 
extracted from the NZF and the New Zealand interRAI-HC has been utilized for 
assessing the reduction in the ACB such as the use of the cross sectional study 
design presents as an inherent limitation and can limit the applicability of the 
findings. 
We have not taken into consideration the medications for Attention Deficit 
Hyperactivity Disorder, menopause, pregnancy, and fertility, as detailed in the 
NZF because these conditions may not be frequently observed in individuals over 
65 years of age. With respect to the prescription of sex hormones, only those 
medications which were recommended for the prevention of osteoporosis and the 
treatment for cancer have been included. We have also not included medications 
for substance abuse, palliative care, anaesthesia, nutrition, rare metabolic 
disorders, medications for the eye, ear, nose and throat, skin, and immunological 
products & vaccines, as the list would have been very extensive. We have not 
included any medication that is administered topically, rectal, vaginal, through 
sprays, inhalation, as a suppository, gel, ear-drops or eye-drops. We cannot 
exclude the risk of systemic anticholinergic effects with these application routes, 
but presume that it is very meagre as there is no conclusive evidence that these 
agents cross the blood-brain barrier and elicit any significant impact on the 
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cognitive function.(221) The dosage and method of delivery (oral or parenteral) 
of all medications were beyond the scope of this study, and have not been taken 
into consideration. Many practical considerations such as the availability of 
medications or funding of individual medications by the Pharmaceutical 
Management Agency (PHARMAC) are also crucial in the decision-making of 
pharmaco-therapeutic regimens while prescribing alternatives to MAP.  
We could not gather information for the anticholinergic activity of the 
medications listed in Table 6.2. 
 
Table 6.2: List of medications in the New Zealand formulary whose anticholinergic activity could not be 
determined 
 
Melatonin Picosulfate sodium Levosimendan Mepolizumab 
Dexamfetamine 
sulphate 
Paraffin liquid Noradrenaline Icatibant acetate 
Methylphenidate 
hydrochloride 
Methylnaltrexone bromide Metaraminol Ivacaftor 
Modafinil Prucalopride Ephedrine salts Pholcodine 
Dihydrocodeine tartrate Ursodeoxycholic acid Dalteparin sodium Benzydamine 
Rizatriptan Colestyramine Tinzaparin sodium Nintedanib 
Ergotamine Pancreatin Bivalirudin Pirfenidone 
Ethosuximide Rifaximin Rivaroxaban Flucloxacillin 
Vigabatrin Milrinone lactate Apixaban Ticarcillin 
Apomorphine Bendroflumethiazide Dabigatran etexilate Cefalexin 
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Benserazide Eplerenone Protamine sulfate Ceftazidime 
Lisuride hydrogen 
maleate 
Adenosine Idarucizumab Cefepime 
Peppermint oil Celiprolol Abciximab Ceftaroline 
Orlistat Minoxidil Eptifibatide Meropenem 
Phentermine Nitroprusside sodium Tirofiban Ertapenem 
Droperidol Ambrisentan Prasugrel Aztreonam 
Ondansetron Bosentan Ticagrelor Lymecycline 
Granisetron Macitentan Alteplase Tigecycline 
Tropisetron Epoprostenol Tenecteplase Amikacin 
Aprepitant Iloprost Tranexamic acid Sodium fusidate 
Fosaprepitant Selexipag Prothrombin complex 
concentrate (human) 
Methenamine hippurate 
Alginate sodium Cilazapril Rosuvastatin Linezolid 
Olsalazine sodium Sacubitril +Valsartan Bezafibrate Daptomycin 
Infliximab Nimodipine Nicotinic acid Teicoplanin 
Adalimumab Nicorandil Acipimox Colistimethate 
Cromoglicate sodium Perhexiline maleate Sodium tetradecyl sulfate Rifabutin 
Rhamnus frangula Hydroxyethylrutosides Aminophylline Dapsone 
Dantron + Poloxamer Isoprenaline hydrochloride Omalizumab Ornidazole 
Itraconazole Disoproxil Nevirapine Entecavir 
Posaconazole Emtricitabine Cobicistat Telbivudine 
Voriconazole Tenofovir Alafenamide Raltegravir Peginterferon alfa-2a 
Amphotericin B Indinavir Elvitegravir Ribavirin 
Caspofungin Ritonavir Dolutegravir Asunaprevir 
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Micafungin sodium Atazanavir Aciclovir Daclatasvir 
Zidovudine Darunavir Valaciclovir Sofosbuvir 
Didanosine Lopinavir + Ritonavir Ganciclovir Ledipasvir + Sofosbuvir 
Lamivudine Rilpivirine Valganciclovir Dasabuvir & Paritaprevir 
+ Ritonavir + Ombitasvir 
& Ribavirin 
Abacavir Efavirenz Foscarnet sodium Elbasvir + Grazoprevir 
Tenofovir Etravirine Adefovir dipivoxil Glecaprevir + Pibrentasvir 
Peginterferon alfa-2a, 
Peginterferon alfa-2a + 
Ribavirin 
Atovaquone Praziquantel Exenatide 
Oseltamivir Pentamidine isethionate Ivermectin Sitagliptin 
Mefloquine Mebendazole Glibenclamide Vildagliptin 
Proguanil Pyrantel Gliclazide Saxagliptin 
Dapagliflozin Teriparatide Denosumab Iron sucrose 
Cyproterone acetate Alendronic acid Leuprorelin acetate Iron polymaltose 
Dutasteride Cholecalciferol Metyrapone Cyanocobalamin 
Nandrolone decanoate Zoledronic acid Ferrous fumarate Hydroxocobalamin 
Terlipressin Strontium ranelate Ferric carboxymaltose Epoetin beta 
Deferoxamine mesilate Deferiprone Eltrombopag Eculizumab 
Lenograstim Pegfilgrastim Plerixafor Etoricoxib 
Mefanemic acid Tenoxicam Gold- sodium 
aurothiomalate 
Penicillamine 
Apremilast Leflunomide Abatacept Etanercept 
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Infliximab Rituximab Ustekinumab Tocilizumab 
Secukinumab Rasburicase Febuxostat Neostigmine metilsulfate 
Fampridine    
 
6.7 Conclusion 
A list of alternatives to MAP was created from a comprehensive review of 
scientific literature and evidence, and is intended to be a useful tool for health 
professionals, and health systems that manage older adults with dementia. The 
implementation of the recommendations for prescribing therapeutic alternatives 
to anticholinergic medications in this vulnerable population along with an 
awareness created among prescribers has the potential to reduce untoward effects 
associated with the prescription of anticholinergic medications, slower cognitive 
decline, and decrease the risk of mortality; supporting individuals with dementia 
to live longer independently.   
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The overarching aim of the thesis was to assess the appropriateness of 
prescription of medications in older adults, and suggest therapeutic alternatives 
for the potentially inappropriate medications with anticholinergic properties in 
individuals with dementia. 
In line with the hypothesis, with the aid of a detailed literature review, in Chapter 
2, we assessed practical applications of the existing criteria for appropriate 
prescribing, and suggested deprescribing as one of the principal ways forward to 
reduce the prescribing of PIMs in older adults. Research conducted globally has 
affirmed that deprescribing of non-essential medications is associated with 
improved health among patients, reduced health-care costs, and decreased 
mortality.(120-122, 240, 241) 
The results of Chapter 3 provide an account of the prevalence of prescription of 
PIMs in older adults of New Zealand (NZ) in different periods, utilizing the Beers 
criteria. Our study reported the prevalence of PIMs for the first time in NZ in a 
high-risk population that had undertaken a comprehensive geriatric risk 
assessment. The most common PIMs prescribed belonged to the class of 
medications prescribed for ailments of the central nervous system, similar to the 
findings of other studies.(14, 146)  
The factors most commonly associated with prescribing PIMs were then 
identified. The results demonstrate a correlation between individuals diagnosed 
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with cancer, dementia, insomnia, depression, anxiety, or those who were 
hospitalized and an increased prescription of PIMs. We noticed a comparable 
trend in different studies conducted world-wide.(22, 170, 172, 174, 178, 181) 
These determinants should be taken into account while considering appropriate 
prescribing.  
As a step forward, we delineated the determinants of inappropriate prescribing in 
the community-dwelling older adults diagnosed with dementia, and lay emphasis 
on the modifiable factors, such as curtailing the prescription of medications with 
anticholinergic properties (MAP), reducing the number of medications 
prescribed, and improving poor self‐health. We observed a high frequency of 
prescription of MAP in older adults with dementia in NZ, analogous to studies 
conducted in the USA and Australia.(145, 203) 
Subsequently, a comprehensive list of the therapeutic alternatives to medications 
with anticholinergic properties prescribed for comorbidities in individuals with 
dementia was developed. This is the first study, which provides a comprehensive 
list of medications listed in the NZ Formulary, sorts the medications with high or 
moderate anticholinergic activity, and low or no anticholinergic activity; and 
suggests alternatives according to the therapeutic classification of medications. 
The incorporation of the alternatives to MAP in the interRAI-HC dataset has been 
successful in theoretically reducing the anticholinergic burden, which enhances 
the significance of the study. The strength of our outlined alternatives to MAP is 
 
Discussion and Future Directions 
145 
 
that they are based on the information contained in guidelines, meta-analyses, 
randomized controlled trials, and rigorous observational studies. The list of 
alternatives to MAP is intended to be a useful tool for health professionals, and 
health systems which manage older adults with dementia. The implementation of 
the recommendations in this vulnerable population along with an awareness 
created among prescribers has the potential to reduce untoward effects associated 
with the prescription of MAP, slower cognitive decline, and decrease the risk of 
mortality; supporting individuals with dementia to live longer independently.   
The unique feature of our study is that our study population included older adults 
with complex care needs in New Zealand. A major asset of the thesis is that a 
nationwide database of a comprehensive geriatric assessment, the international 
Resident Assessment Instrument-Home Care (interRAI-HC) was set up for the 
first time to capture a suite of clinical and sociodemographic data. The interRAI-
HC assessment permits comparing data of residents with similar needs, so that a 
uniform best practice approach to provide care can be utilized. The selection bias 
has been overlooked in this study population due to the wide prescription 
coverage using the interRAI-HC dataset.(29) A standardized interRAI-HC 
assessment performed by trained healthcare professionals has the usefulness of 
providing valid clinical, social, and functional information.(27) Several 
determinants included in the multivariate regression model, such as self-reported 
health, living status, and cognition, are seldom accessible in studies that use the 
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administrative claims data; hence, this study provides a unique perspective to the 
factors associated with prescription of PIMs in older adults. Our findings also 
focus on interRAI-HC assessments as a significant opportunity to re-evaluate 
prescribing in a cohort of vulnerable older adults requiring complex care needs. 
The list of alternatives to MAP is based on the medications available in the NZ 
formulary, and hence intended to be a useful tool for health professionals, and 
health systems in NZ which manage older adults with dementia. There may be a 
slight variation to the availability of medications with anticholinergic properties 
and their alternatives based on the therapeutic class of drugs in different countries. 
7.2 Limitations 
Some of the medications enumerated in the Beers criteria were not available in 
NZ, and hence, not included in the studies conducted as a part of the thesis. The 
Beers criteria were applied retrospectively to the various studies, and certain 
aspects of the criteria might not have been applicable and/or considered by 
prescribers during the study period. A few diagnoses mentioned in the Beers 
criteria were excluded from the analyses as the interRAI-HC dataset had not 
capture them. The geriatric risk assessments were conducted in older adults living 
in the community with complex care needs, which is different from surveyed 
populations of older adults living in the community. The findings of this study 
might not be applicable to community‐dwelling older adults in various countries 
because of variances in the population, health systems, prescribing guidelines, 
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and the cost of medications, as all these factors influence prescribing patterns; 
however, country‐specific guidelines can be developed using this information. 
The categorization of medications in Chapter 6 was solely based on the 
anticholinergic properties of medications, irrespective of their ‘safety profile’ The 
applicability of the alternatives for MAP in different countries cannot be 
ascertained as the medications listed in the tool have been extracted from the NZ 
formulary, and the NZ interRAI-HC has been utilized for assessing the reduction 
in the ACB. Information on the dosage and method of delivery (oral or parenteral) 
of all medications were beyond the scope of the various studies conducted. 
 
7.3 Future Directions 
The authors envision the findings of the thesis as an initial step to more robust 
clinical intervention studies. Geriatric risk assessments should emphasize 
comprehensive medication reviews. A way forward to reduce PIMs is to 
encourage deprescribing. The development of evidence based Deprescribing 
guidelines and the inclusion of Deprescribing modules are a priority for the 
adequate care of older adults. Health professionals should be made aware of the 
potential risks associated with the prescription of PIMs, and recommendations 
should be made to minimize their use over time. It would be best to see if PIMs 
prescription change over time led to reduced rate of relevant clinical outcomes 
using a longitudinal cohort design. 
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Prescribers are recommended to take into consideration the alternatives to MAP 
as a decision support tool, along with rationalizing prescribing in older adults 
with dementia to enhance safe pharmacotherapy. We also suggest health 
professionals to implement these recommendations for prescribing in adults more 
than 65 years of age to prevent the onset of cognitive impairment and dementia. 
More studies are required to validate the tool in actual clinical settings. 
The integration of the list of pharmacological alternatives to the currently 
prescribed MAP in the hospital information systems (HIS) may have the potential 
to improve therapeutic outcomes in the vulnerable population of older adults. 
The prescriber and the patient or the care-taker should discuss and review the 
benefits and drawbacks of both the prescribed and over-the-counter medications 
the patient is being administered, and make an informed decision to switch to 
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Appendix 1: List of medications in Beers criteria which are unavailable or not subsidized in New Zealand 
Carbinoxamine Guanfacine Secobarbital Oxaprozin 
Clemastine Reserpine Quazepam Piroxicam 
Cyproheptadine Dronedarone Clorazepate Tolmetin 
Dexbrompheniramine Amoxapine Chlordiazepoxide Carisoprodol 
Hydroxyzine Desipramine Eszopiclone Cyclobenzaprine 
Meclizine Protriptyline Zolpidem Chlorzoxazone 
Trihexyphenidyl Amobarbital Zaleplon Metaxalone 
Belladona Alkaloids Butabarbital Isoxsuprine Cilostazol 
Clidinium-
Chlordiazepoxide 
Butalbital Methyltestosterone Methocarbamol 
Dicyclomine Mephobarbital Desiccated Thyroid Rosiglitazone 
Hyoscyamine Pentobarbital Glyburide Thiothixene 
Guanabenz Estazolam Diflunisal Nizatidine 
Meclofenamate Armodafinil Etodolac Amphetamine 




Darifenacin Fesoterodine Zuclopenthixol Acetate Trimethobenzamide 
Trospium Loxapine Perphenazine Perphenazine-
Amitriptyline 
Mesoridazine Dofetilide Ibutilide Ketolorac 
Pemoline Paliperidone Dexchlorpheniramine Eplerenone 




Meperidine Dosulepin Tetracosactide Chlorazepate 
Mineral Oil Etoricoxib Pimozide Rabeprazole Sodium 
























Appendix 2.1: The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) 
guidelines 
 
Item No Location 
Title and abstract 1 Title and abstract 
Introduction 
Background/ rationale 1 Introduction 
Objectives 1 Introduction 
Methods 
Study design 2 Methods 
Setting 2 Methods 
Participants 2.2 Methods-Study population 
Variables 2.4 Methods-PIMs exposure 
Data sources/ measurement 2.1 Methods-Data source 
Study size 2.2 Methods-Study population 
Quantitative variables 2.4 Methods-Covariates 
Statistical methods 2.5 Methods-Statistical analyses 
Results 
Participants 3 Results 
Descriptive data 3 Results 
Outcome data 3.1, 3.2, 3.3 Results 
Main results 3 Results- Sociodemographic and clinical 
predictors 


















Appendix 2.2: List of medications in Beers criteria which are unavailable or not subsidized in New Zealand 
 
Carbinoxamine Guanfacine Secobarbital Oxaprozin 
Clemastine Reserpine Quazepam Piroxicam 
Cyproheptadine Dronedarone Clorazepate Tolmetin 
Dexbrompheniramine Amoxapine Chlordiazepoxide Carisoprodol 
Hydroxyzine Desipramine Eszopiclone Cyclobenzaprine 
Meclizine Protriptyline Zolpidem Chlorzoxazone 
Trihexyphenidyl Amobarbital Zaleplon Metaxalone 
Belladona Alkaloids Butabarbital Isoxsuprine Cilostazol 
Clidinium-
Chlordiazepoxide 
Butalbital Methyltestosterone Methocarbamol 
Dicyclomine Mephobarbital Desiccated Thyroid Rosiglitazone 
Hyoscyamine Pentobarbital Glyburide Thiothixene 
Guanabenz Estazolam Diflunisal Nizatidine 
Meclofenamate Armodafinil Etodolac Amphetamine 




Darifenacin Fesoterodine Zuclopenthixol Acetate Trimethobenzamide 
Trospium Loxapine Perphenazine Perphenazine-
Amitriptyline 
Mesoridazine Dofetilide Ibutilide Ketolorac 
Pemoline Paliperidone Dexchlorpheniramine Eplerenone 




Meperidine Dosulepin Tetracosactide Chlorazepate 
Mineral Oil Etoricoxib Pimozide Rabeprazole Sodium 


























Appendix 3.1: List of medications termed potentially inappropriate for the diagnosis of dementia according to 









Clemastine Desipramine Quazepam Darifenacin 
Cyproheptadine Protriptyline Clorazepate Trospium 
Dexbrompheniramine Amobarbital Chlordiazepoxide Flavoxate 
Hydroxyzine Butabarbital Eszopiclone Brompheniramine 
Meclizine Butalbital Zolpidem Alfentanil 
Trihexyphenidyl Mephobarbital Zaleplon Dexchlorpheniramine 
Belladona Alkaloids Pentobarbital Fesoterodine Meclizine 
Clidinium-Chlordiazepoxide Estazolam Loxapine Doxylamine 
Dicyclomine Armodafinil Perphenazine Triprolidine 



















Item No Location 
Title and abstract                       1 Title and abstract 
                                                        Introduction 
Background/ rationale  1 Introduction 
Objectives 1 Introduction 
                                                           Methods 
Study design 3 Methods 
Setting 3 Methods 
Participants 3.2 Methods-Study population 
Variables 3.3 Methods-PIMs exposure 
Data sources/ measurement 3.1 Methods-Data source, Diagnosis of Dementia 
Study size 3.2 Methods-Study population 
Quantitative variables 3.4 Methods-Covariates 
Statistical methods 4 Methods-Statistical analyses 
                                                            Results 
Participants 5 Results 
Descriptive data 5 Results 
Outcome data 5.1, 5.2 Results 
Main results 5.1, 5.2 Results- Sociodemographic and clinical predictors 
Other analyses 5 Results 
                                                         Discussion 
Key results 
6 Discussion 
































Appendix  4.1:  Pharmacological alternatives for the currently prescribed MAP for older adults with dementia presenting with co-
morbidities 
 New Zealand formulary medications High or moderate anticholinergic 
activity medications  






Nervous system A. Psycholeptics 
1. Hypnotics and Sedatives (212, 226-231) 






Benzodiazepine related  medications  
Zopiclone 

























































2. Anxiolytics (212, 226-231) 




















































Non-selective monoamine reuptake inhibitors 
Imipramine 
Clomipramine 









iv. B Blockers 
 







































































3. Antipsychotics: (212, 228, 230, 242-248) 
i. Atypical 2nd generation Antipsychotics: 
Benzamides 
Amisulpride   
Diazepines, oxazepines, thiazepines and 



























































ii. 1st generation antipsychotics 




Phenothiazines with piperazine structure 
Prochlorperazine 
Trifluoperazine 


































































Phenothiazines with piperazine structure 
Fluphenazine decanoate 
Thioxanthene derivatives 
Flupentixol decanoate  
Zuclopenthixol decanoate 
Diazepines, oxazepines, thiazepines and 
oxepines   
Olanzapine pamoate 











































4. Medications for bipolar disorder(212, 228, 230, 
242-248) 
Benzodiazepines 











































1. Antidepressants(94, 166, 212, 222, 228-230, 249-256)  























































Dosulepin,   
Maprotiline HCl 
 




iv. Monoamine oxidase A inhibitors 
Moclobemide 
 



































































2. Psychostimulants, agents used for ADHD 
and Nootropics 










3. Anti-Dementia  medications (231, 234) 
Anticholinesterases 
Donepezil hydrochloride   
Rivastigmine  
Galantamine  



















N06DA04    
 
N06DX01  
C. Analgesics(212, 228, 229, 231, 232) 
1. Non-opioid analgesics 














Other analgesics and antipyretics  
Paracetamol 







2. Opioid analgesics 
Codeine phosphate 






















































































D. Antimigraine preparations(228, 231, 232) 
1. Treatment of acute migraine 
i. Analgesics 





iii. Ergot alkaloids 






























2. Prophylaxis of migraine 











E. Antiepileptics(212, 226-229, 231, 234) 





Barbiturates and derivatives 
Phenobarbital  
Primidone 
Hydantoin derivatives  
Phenytoin 






























































































































Febrile Convulsions  














F.  Anti-Parkinson  medications(212, 228, 231) 







Dopa and dopa derivatives 
Levodopa+ Benserazide* 









































Lisuride hydrogen maleate* 







2. Anticholinergic agents 




































     
Alimentary tract 
and metabolism 
 A. Dyspepsia and gastro-oesophageal reflux 
disease(231) 
1. Antacids 





















Sodium bicarbonate  
Mineral supplements 












































B. Antispasmodics and other  medications 

















Synthetic anticholinergics, quaternary 
ammonium compounds  
Propantheline bromide 
 
2. Other Antispasmodics 
Synthetic anticholinergics, esters with tertiary 
amino group 













































C. Ant obesity preparations, excl. diet 
products 





Peripherally acting: Orlistat* 
Centrally acting: Phentermine* 
A08AB01 
A08AA01 
D. Antiemetics and Anti-nauseants(212, 228, 231, 

























































































































E. Ant secretory  medications and mucosal 
protectants                  
Anti-Hpylori and NSAID associated ulcers  




























































































4. Chelates and complexes 
Sucralfate 
 
















F. Acute Diarrhoea(212, 228-231) 




2. Anti-motility  medications 
Opium alkaloids and derivatives 
Codeine phosphate   
Diphenoxylate hydrochloride  
Loperamide hydrochloride  
Belladonna alkaloids, tertiary amines  









Diphenoxylate    
Loperamide (M)  
 





















G. Chronic bowel disorders(212, 228, 231, 232) 
1. Amino salicylates 









3.  Medications affecting the immune 
response: 
Azathioprine 

























































H. Medications for constipation(212, 229, 231, 232) 
Laxatives 
1. (Bulk-forming) 
Psyllium husk powder 
Sterculia 
Rhamnus frangula*  
 
2. Contact laxatives 
Bisacodyl 
Dantron + Poloxamer* 
 
3. Softeners, emollients  
Docusate sodium 




































4. Faecal softeners 
Docusate sodium 
Docusate sodium + Sennoside B 
Paraffin liquid* 
 







6. Bowel cleansing agents 
Macrogols  
Phosphates 






















A06AA01   
 
 















7. Peripheral opioid-receptor antagonists 
Methylnaltrexone bromide* 
 








I.  Medications affecting intestinal secretions 
1. Bile acid derivates 
Ursodeoxycholic acid* 
 
2. Bile acid sequestrants 
Colestyramine* 
Pancreatin* 

















A06AD11   






A. Positive Ionotropic  medications(212, 226, 228) 
1. Cardiac Glycosides 
Digoxin 
 











B. Diuretics(212, 226, 228, 231-234) 
1 i. Low-ceiling diuretics, thiazides 
Bendroflumethiazide* 
ii. Low-ceiling diuretics, excl. Thiazides 
Chlortalidone 
Sulfonamides, plain  
Indapamide hemihydrate 
 
2.  High-ceiling diuretics 











































3. Potassium-sparing diuretics  





4. Potassium-sparing diuretics with other 
diuretics 
Amiloride + Furosemide  
 
Amiloride + Hydrochlorothiazide 
 
5. Osmotic Diuretics 
Mannitol 
 









                       
 













































C. Anti-arrhythmic  medications(212, 226, 228, 230-
232, 260) 
Supraventricular and Ventricular 
arrhythmias 
Class Ia Anti-arrhythmic 
Disopyramide 
Class Ib Anti-arrhythmics 
Lidocaine  




Class II Anti-arrhythmics  
B Blockers  
Non-selective 
Propranolol hydrochloride 
































































Class III Anti-arrhythmics 
Amiodarone 
 






























































Propranolol hydrochloride  
Timolol 
Sotalol hydrochloride  
Nadolol 
Selective 
Metoprolol succinate  
Metoprolol tartrate 
Atenolol  
Bisoprolol fumarate  
Celiprolol hydrochloride*  
Alpha and Beta blocking agents 




























E. Anti-hypertensives(212, 226, 228, 231-233) 
1. Vasodilator anti-hypertensives 
Hydrazinophthalazine derivatives  
Hydralazine hydrochloride  
































3. Centrally acting antihypertensive 
medications 
Methyldopa 




























































4. Peripherally acting  antihypertensive 






5. Medications affecting the renin-angiotensin 
system 
i. Angiotensin converting enzyme inhibitors 
(ACE-I) 
Captopril  
































































Quinapril + Hydrochlorothiazide 
 
Cilazapril* + hydrochlorothiazide  
 
 ii. Angiotensin-II receptor antagonists (ARB) 
Candesartan cilexetil 
Candesartan + Hydrochlorothiazide  
 
Losartan potassium 
Losartan + Hydrochlorothiazide 
 
Sacubitril + Valsartan* 
 Heart Failure 
ACEI/ARB+B-Blocker+Spironolactone, 


























Candesartan + Hydrochlorothiazide  
 
Losartan 



























F. Antianginal medications(212, 228, 229, 231, 232) 
1. Organic nitrates 
Glyceryl trinitrate  
Isosorbide mononitrate 
 







3. Benzothiazepine derivatives 
Diltiazem hydrochloride  
 









Felodipine   




















































G. Sympathomimetics(231, 232) 

































Ephedrine salts*  
 
















Low molecular weight heparins  
Dalteparin sodium*  
Enoxaparin sodium  
Tinzaparin sodium* 
 


































Vitamin K antagonists 
Warfarin 
Direct factor Xa inhibitors 
Rivaroxaban*  
Apixaban* 
Direct thrombin inhibitors 
Dabigatran etexilate*  
 



















I. Stroke Management(212, 228, 229, 232) 
Platelet aggregation inhibitors  
Clopidogrel  
Aspirin  

























J. Fibrinolytic medications 
Alteplase*  
Tenecteplase*  
   
B01AD02 
B01AD11 
K. Antifibrinolytic medications and 
haemostatics 
Tranexamic acid*  
 
Blood-related products: 
Prothrombin complex concentrate (human)* 
   
 
B02AA02 
L. Lipid-regulating medications(231, 232) 
1. Statins  
 















Pravastatin sodium  
Atorvastatin  
Rosuvastatin*  
HMG CoA reductase inhibitors in 
combination with other lipid modifying agents 
Ezetimibe + simvastatin 
 






















































M. Local Sclerosants 
Sodium tetradecyl sulfate* 
   
C05BB04 
     
Respiratory 
System 



























B. Chronic Obstructive Pulmonary Disease(212, 
228, 231, 232) 













































C. Antihistamines(212, 228, 229, 232, 233) 
1. Non-sedating  







































































D. Allergen immunotherapy 
Omalizumab* 
Mepolizumab* 











   
B06AC02 









Bromhexine hydrochloride Bromhexine hydrochloride R05CB02 
H. Cough and cold Preparations 
1. Cough Suppressants  

































































































































Protein kinase inhibitors  
Nintedanib* 










     
Anti-infectives for 
systemic use 
A. Antibacterial agents(212, 228, 229, 231, 232) 
1. Penicillins 







ii. Penicillinase-resistant Penicillins 
Flucloxacillin* 
 
iii.  Penicillins with extended spectrum  
Amoxicillin 



















































iv. Anti-pseudomonal penicillins 
Ticarcillin* + Clavulanic acid 
Piperacillin + Tazobactam   
 
2. Cephalosporins, carbapenems, and other 
beta-lactams 
First generation cephalosporins 
Cefalexin*  
Cefazolin  
Second generation cephalosporins 
Cefoxitin    
Cefuroxime 
Cefaclor   
Third generation cephalosporins 
Cefotaxime*   




























































Cefepime hydrochloride*  
Others 





Imipenem + Cilastatin   
 














































































6.  Lincosamides  
Clindamycin 
 
















































J01FA01   


















9. Other antibacterials 
Sodium fusidate*  
Nitrofurantoin  



































































1. Antituberculosis medications 
i. Hydrazides  
Isoniazid 























































D. Antifungal medications(231, 232) 




Posaconazole*   
 
2. Polyene antifungals 
Amphotericin B*  
Nystatin  
 











































E. Anti-viral medications(212, 232) 
1. HIV infection 







Tenofovir alafenamide*  
 





















































Lopinavir + Ritonavir*  
 






Combination  medications 
 
iv. Other antiretrovirals 
Cobicistat*  
Raltegravir* 
Elvitegravir*   
Dolutegravir*  
 

































































3. Cytomegalovirus infection 




Phosphonic acid derivatives 
Foscarnet sodium* 
 
4. Viral hepatitis 
i. Chronic hepatitis B 
Nucleoside reverse transcriptase inhibitors 
Lamivudine* 






















































Ledipasvir* + sofosbuvir   
Dasabuvir* & Paritaprevir* + Ritonavir* + 
Ombitasvir* & Ribavirin*  
Elbasvir* + Grazoprevir* 
Glecaprevir* + Pibrentasvir*  Peginterferon alfa-
2a* 











































Amantadine hydrochloride   




















Atovaquone* + Proguanil* 


















































   
A01AB04 
P01CX01 
K. Pneumocystis pneumonia(229) 











1. Threadworms,  Ascaricides, Hookworms 



















2. Tapeworm infections, Schistosomicides 




































   
Endocrine system A. Diabetes(94, 229, 231, 232) 

















4. Other medications 
Alpha glucosidase inhibitors  
Acarbose 













































Metformin + Sitagliptin* 
Metformin +Vildagliptin* 
Metformin + Saxagliptin* 






 Diabetic neuropathy 


























 B. Thyroid and anti-thyroid medications(231, 
232) 
1. Thyroid hormones 
Levothyroxine sodium 
 






















 C. Corticosteroids(231) 




2. Glucocorticoid therapy 

































 D. Sex hormones(231, 232) 






















iii. Progestogens and estrogens, fixed 
combinations 
Estradiol + Norethisterone 
Estrogens conjugated equine + 
Medroxyprogesterone 
 














Estradiol + Norethisterone 



















































 E.  Posterior pituitary hormones  











 F. Medications affecting bone metabolism(231, 
232) 
1. Osteoporosis 













Parathyroid hormones and analogues 
Teriparatide* 
 
ii.  Bisphosphonates and other medications 
affecting bone metabolism 
Alendronic acid* 

































 G. Other endrocine medications(231, 232) 
Prolactin inhibitors 
Bromocriptine 












Gonadotropin releasing hormone analogues 
Leuprorelin acetate* 






     
Genitourinary 
system 
A. Vaginal and vulval infections(231, 232) 
Imidazole derivatives  
Clotrimazole + Fluconazole 
 





















































D.  Medications used for urinary frequency 
and  incontinence 
Oxybutynin 





















     
Blood and blood 
forming organs 
A. Anaemias(231, 232) 
1. Iron deficiency anaemia: 
Iron 
Iron bivalent, oral preparations 
Ferrous fumarate* + Folic acid 
Ferrous sulfate + Ascorbate sodium 








































4.  Iron overload 



















































B.  Platelet disorders 
Idiopathic thrombocytopenic purpura 
Systemic hemostatics 
Eltrombopag* 




C.  Neutropenia(231) 













D.   Medications used to mobilise stem cells 
Plerixafor* 
   
L03AX16 
     
Musculo-skeletal 
System 













Acetic acid derivatives and related substances 
Sulindac 
Diclofenac potassium  
Diclofenac sodium   









Salicylic acid derivatives 
Aspirin 













































































































































Tumor necrosis factor alpha inhibitors 
Etanercept*   
Infliximab*  
Adalimumab* 




Tocilizumab*   








































































 F. Medications used in neuromuscular 
disorders(231) 
i. Anticholinesterases 
Neostigmine metilsulfate*  
Pyridostigmine bromide 
 
ii. Immuno-suppressant therapy:  
Corticosteroids 
 



































 G. Skeletal muscle relaxants(231) 
Baclofen  
Dantrolene sodium  
Diazepam  
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